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SUMMARY
We have advanced considerably in the past
2 to 3 years in understanding the molecular
mechanisms of consolidation, retrieval, and
extinction of memories, particularly of fear
memory. This advance was mainly due to
pharmacological studies in many laboratories
using localized brain injections of molecularly
specific substances. One area in which significant
advances have been made is in understanding
that many different brain structures are
involved in different memories, and that often
several brain regions are involved in processing
the same memory. These regions can cooperate
or compete with each other, depending on
circumstances that are beginning to be
identified quite clearly. Another aspect in
which major advances were made was retrieval
and post-retrieval events, especially extinction,
pointing to new therapeutic approaches to fear-
motivated mental disorders.
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INTRODUCTION
Most of what we know about the biochemistry
of memory processes has come from pharmaco-
logical experiments. We recently published several
extensive reviews on this subject in relation to
memory consolidation (Izquierdo & McGaugh,
2000; McGaugh & Izquierdo, 2000), the dichotomy
between short- and long-term memory (Izquierdo
et al., 1999; Izquierdo et al., 2002), retrieval (Barros
et al., 2003), and extinction (Vianna et al., 2003).
In addition, several other recent and excellent
accounts of special aspects of these subjects have
emerged: the role of glutamate receptors in memory
processes (Castellano et al., 2001; Riedel et al.,
2003), the molecular pharmacology of extinction
(Myers & Davis, 2002), molecular models of
human cognition deficits involving alterations of
phosphorylation of the transcription factor cAMP-
response element binding protein (CREB)
(Weeber & Sweatt, 2002), or disruptions of
calcium/calmodulin-dependent protein kinase (PK)
II activity (Weeber et al., 2003), the role of the
amygdala in consolidation (McIntyre et al., 2003)
and extinction (Davis et al., 2003) and others. A
recent book edited by Riedel and Platt (2003)
contains chapters reviewing most aspects mentioned
above and others in detail.
Here we review papers published between
mid-2001 and October 2003 on pharmacological
findings that shed light on the biochemistry of
consolidation, retrieval, and extinction that are
(C) 2004 Freund & Pettman, U.K. 159160 IVAN IZQUIERDO ET AL.
therefore generally not covered by the articles
mentioned above. Topics that are being currently
studied in this laboratory, but for which the results
are still a long way from becoming definitive, will
not be reviewed. These areas include the role of
the cellular prion protein (Martins e t al., 2002;
Coitinho et al., 2002; Martins et al., 2003) and the
role of brain ectonucleotidases in memory processes
(Pereira et al., 2002). The two subjects may be
interrelated (Pereira et al., 2001).
MEMORY MECHANISMS: A GENERAL VIEW
Pharmacological experiments, often corrobo-
rated by studies using genetic manipulation, have
established the major molecular mechanisms of
memory consolidation and certain mechanisms
involved in retrieval and extinction. The most
useful studies have usually been carried out using
small and slow stereotaxic infusions of drugs into
restricted brain areas. The infused material reaches
not more than mm of brain tissue and diffuses
away from the infusion site with a time constant of
30 min or less (Martin, 1991; Ardenghi et al., 1997;
Barros et al., 2000, 2001). Larger or faster infusions
yield data that are difficult to interpret and will not
be commented upon here. In certain instances,
systemic administration produced relevant findings,
however, depending on the drug chosen.
Most studies have been carried out on the
hippocampus, the brain structure most involved in
memory processing and/or the main structure
responsible for the consolidation, retrieval, and
extinction of many tasks in animals and humans
(Eichenbaum et al., 1996; Bunsey, 1996; Izquierdo
& Medina, 1997; Izquierdo & McGaugh, 2000;
Izquierdo et al., 2002; Barros et al., 2003; Sacchetti
et al., 1999). Several studies, however, have
addressed other brain structures thought to be
responsible for the consolidation of certain types
of fear memory, such as the amygdala (Miser-
endino et al., 1990; Bevilaqua et al., 1997; Myers
& Davis, 2002), various regions of the cortex
(Ardenghi et al., 1997) and, as will be seen below,
the nucleus accumbens (Sargolini et al., 2003) and
the striatum (Prado-Alcali et al., 2003). Brioni
(1993) was perhaps the first to state formally that
consolidation is not the result of the operation of
any single brain structure but of many structures
that are linked to one another and with the hippo-
campus, as borne out by many experiments
(Ardenghi et al., 1997; Izquierdo et al., 1997;
lzquierdo & Medina, 1997; Sacchetti et al., 1999;
Izquierdo & McGaugh, 2000; Bonini et al., 2003;
Rosatto et al., 2003). The days in which the
hippocampus was attributed a role only in spatial
tasks (Morris et al., 1986) or contextual learning
(Hirsh, 1974) are gone; hundreds of papers on
brain lesions, functional inactivation, drug effects
in animals, and functional magnetic resonance in
humans attest to the generality of the role of the
hippocampus and its connections in many forms of
memory (see Eichenbaum et al., 1996; Izquierdo &
Medina, 1997; McGaugh & Izquierdo, 2000).
In the CA1 region of the rat hippocampus,
consolidation processes involve initially the
activation of glutamate N-methyl-D-aspartate
(NMDA; Morris et al., 1986; Izquierdo et al.,
1992), alpha-amino-3-hydroxy-5-methylisoxazole-
4-propionic acid (AMPA; Jerusalinsky et al., 1992,
1992) and metabotropic receptors (m-GluRs;
Bianchin et al., 1996), enhanced by the influence
of presynaptic /-PKC on the vesicle-mobilizing
substrate GAP-43 (Colley & Routtenberg, 1993;
Cammarota et al., 1997; Routtenberg, 2000;
Paratcha et al., 2000) and by nitric oxide (NO),
carbon monoxide (C), and the platelet-activating
factor released from the postsynaptic terminal
(Izquierdo et al., 1995; Medina & Izquierdo, 1995)
with the intervention of PKG; Bemabeu et al.,
1996). At this early stage, the main brake on
memory formation is the widespread net of
GABAA receptors acting simultaneously in CA1,
amygdala, medial septum, cortex, and other parts
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Right after training, post-synaptic 13-PKC activity
(Paratcha et al., 2000; Routtenberg, 2000), PKA
(Bemabeu et al., 1997) and calcium/calmodulin-
dependent PK II (CaMKII) activity is enhanced;
the latter phosphorylates the GluR1 subunit of the
AMPA receptor (Cammarota et al., 1998). In rat
hippocampus, high levels ofAMPA binding follow
single aversive training experiences (Cammarota et
al., 1996). Protein kinase A, PKC, and CaMKII
phosphorylate several substrates. Inhibitors of
these enzymes given immediately post-training
into the CA1 region of the hippocampus cancel
memory consolidation (Izquierdo & Medina,
1997). Gene expression and protein synthesis at
that time are crucial for long-term, but not for
short-term memory formation (Igaz et al., 2002).
In the first hour after training, PKA, PKC, and
CaMKII enzyme activity declines and consoli-
dation becomes gradually less sensitive to
inhibitors. At that time, however, hippocampal
PKA is essential for maintaining short-term
memory alive for the next 3 to 5 h (Vianna et al.,
2000). At 2 to 3 h after training, the activity of
PKA increases again in CA1 and this--together
with a parallel activation of mitogen-activated
kinase (MAPK) pathwaysmis essential for long-
term memory to become established. This activity
depends on the previous activation of NMDA
receptors in CA1 by training (Cammarota et al.,
2000) and, in the case of PKA, on the preceding
immediate post-training PKA peak mentioned
above (Vianna et al., 2000).
The late wave ofPKA and extra-cellular signal-
regulated kinase (ERK) activity in CA1 coincides
with an an increased phosphorylation of the
transcription factor CREB and with a second wave
of sensitivity to inhibitors of gene expression and
protein synthesis given into CA1 (Igaz et al.,
2002). Early studies on RNA and protein content
measured at different times after behavioral
training have signaled the existence of this double
wave of metabolic activity in the hippocampus as
necessary for long-term memory formation
(Matthies, 1989). At this stage, memory is
sensitive to the facilitator role ofdopamine D and
13-noraflrenergic and the deleterious influence of
serotonin (5HT-1A) receptors in CA1 and else-
where on memory consolidation, which extends up
to 6 h post-training (Ardenghi et al., 1997).
The hippocampus is known to be essential for
retrieval (Squire et al., 1992; Eldridge et al., 2000;
Corcoran &Maren, 2001). Other brain structures,
however, are also involved. Recent studies in rats
show that retrieval of one-trial inhibitory avoidance
requires intact AMPA receptors in CA1, entorhinal
cortex, parietal cortex, and amygdala; intact
NMDA receptors in the anterior cingulate cortex;
and intact glutamate mGluRs in CA1 and in the
entorhinal, parietal, and anterior cingulate cortex,
but not in the amygdala. In addition, retrieval
requires normal PKA and ERK activity (Barros et
al., 2000) in all these brain structures.
The biochemical requirements of extinction
have been examined for a variety of conditioned-
fear tasks in recent years, and the findings are
summarized in Myers and Davis (2002), Bahar et
al. (2003) and Vianna et al., (2003). Pharma-
cological studies have shown that gene expression,
protein synthesis, and PKA mitogen-activated
protein kinase (MAPK)/ERK activity in the hippo-
campus and basolateral amygdala are necessary for
the generation of extinction, beginning at the first
nonreinforced retention test. Variations with the
task and the involvement of other structures in
parallel to and/or instead of the hippocampus and
amygdala are discussed by Vianna et al., (2003).
One structure is the insular cortex in the case of
conditioned taste aversion (Berman& Dudai, 2001).
GLUTAMATE RECEPTORS AND
RELATED MECHANISMS
The effect on learned behavior of NMDA
receptors blockade induced by 2-amino-5-phos-
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restricted brain areas is conventionally taken as an
indication that such areas are crucially involved in
the early stages of memory consolidation (Morris
et al., 1986; Izquierdo et al., 1992). Recently, the
blockade of NMDA receptors in the prelimbic
cortex was found to induce amnesia for odor-
reward associative learning (Tronel & Sara, 2003);
When infused into the dorsal striatum, AP5
interferes with memory consolidation of spatial
learning (De Leonibus et al., 2003); AP5
introduced into the telencephalon of the goldfish
Carassius auratus blocks avoidance memory (Xu
et al., 2003), intra-hippocampal AP5 blocks the
learning of paired-associates (Day et al., 2003),
and intra-accumbens infusion of AP5 or the
AMPA receptor antagonist, DNQX, blocks
memory of an object-recognition task in mice
(Sargolini et al., 2003). In CA3, NMDA receptors
have been recently reported to be critical for one-
trial learning (Nakazawa et al., 2003). So, new
tasks, various brain structures, and one extra
species have been added to the bibliography on the
role ofNMDA receptors in memory consolidation.
In addition, the retrograde amnesia induced by
AP5 for one-trial avoidance was shown to have a
different time course during the onset of its effect,
depending on the brain structure into which it is
infused: CA1, basolateral amygdala, and entorhinal,
posterior parietal, or anterior cingulate cortex
(Rosatto et al., 2003). Thus, it seems that the
NMDA-receptor-mediated role of each region in
consolidation starts at a different time. Clearly,
everyday it becomes more evident that different
tasks involve different brain areas, that these are
engaged at different times, and that no learning
type depends exclusively on any one given brain
area. One curious result in this connection is the
finding that AP5 given into the insular cortex at
doses that block conditioned taste aversion do not
prevent the animals from learning how to attenuate
neophobia; in contrast, scopolamine does prevent
such learning (Guti6rrez et al. 2003). In habituation
to a novel environment, a nonassociative learning
that, to an extent, involves the attenuation of
neophobia, AP5 given into the hippocampus
instead of into the cortex has a clear inhibitory
effect (Vianna et al., 2000).
Extinction is a form of learning in which
animals previously trained to associate a cue
(conditioned stimulus, CS) with a reinforcement
(unconditioned stimulus, US) are required to
associate the cue with the lack of reinforcement;
i.e., to change the previous CS-US association into
a CS-no US association (Myers & Davis, 2002;
Vianna et al., 2003a, 2003b). The consolidation of
extinction requires the transfer from a NMDA-
independent to a NMDA-dependent memory
(Santini et al., 2001). The requirement ofNMDA
receptors for the extinction of aversive tasks at the
time of the first extinction trial has been shown by
the use of AP5 in both the amygdala for
conditioned startle (Falls et al., 1992) and the
hippocampus for one-trial avoidance (Szapiro et
al., 2003).
The precise synapses at which NMDA
receptors participate in consolidation in the hippo-
campus or elsewhere are generally not known and
are vaguely hinted at. For example, the Schaeffer
collateral synapses with CA1 (Izquierdo et al.,
1992) and the synapses between the mossy fibers
and CA3 (Nakazawa et al., 2003) are highly
suspect of being involved. In the amygdala, micro-
dialysis techniques have shown that the visceral
input mediating taste-memory formation is
glutamatergic (Miranda et al., 2002). So far,
morphologic changes in synapses (i.e., Geinisman
et al., 2001) furnish better information about
which synapses might be involved in each learning
task than do pharmacologic or genetic findings.
The precise aspects of memory consolidation
that are blocked by NMDA receptor inhibitors are
also not known. A very elegant study using intra-
hippocampal and intra-amygdala infusions of AP5
suggested that different aspects of one-trial
avoidance are regulated by NMDA receptors in
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amnesic effect of intra-hippocampal but not intra-
amygdala AP5, indicating that the hippocampus is
in charge of the contextual/spatial aspects of
memory for this task, whereas NMDA receptors in
the amygdala would be in charge of its aversive
aspects (Roesler et al., 2003; see also Sanders &
Fanselow, 2003).
Ebselen, an agent with oxidant activity at
NMDA receptors, hinders memory formation
(Porciuncula et al., 2002). When infused into the
amygdala or given systemically, D-cycloserine, a
blocker of the inhibitory glycine site at NMDA
receptors, facilitates NMDA-mediated extinction
of conditioned fear (Walker et al., 2002; Myers &
Davis, 2002).
Which subunits of the NMDA receptor are
important for the role of this receptor in memory
formation? AP5 blocks the function of the entire
NMDA receptor complex. The results of transgenic
mouse studies point to the NR1 subunit in the
hippocampus as being critical for place perception
and spatial learning (Wilson & Tonegawa, 1997).
Cammarota et al. (2000) reported a transient
increase of the NR1 subunit in rat hippocampus
after inhibitory avoidance training. Selective
blockade of NR2B-subunit-containing NMDA
receptors with ifenprodil given in the lateral
nucleus of the amygdala disrupts the acquisition
but not the expression of fear conditioning
(Rodrigues et al., 2002). Possibly NMDA
receptors composed of different subunits are
involved in different tasks in different areas of the
brain. Data from genetic and pharmacologic
approaches can als o show discrepancies (Day &
Morris, 2001). When this occurs, trusting the
pharmacologic approach is usually wise because,
unlike the genetic approach, the pharmacologic
approach is (a) reversible; (b) can be timed with a
degree of precision; (c) does not allow for
developmental corrections of the change induced;
and (d) does not affect the genetic pool of the
animal under observation (Routtenberg, 1995).
As shown years ago, both AMPA/kainate
receptors (Jerusalinsky et al., 1992) and mGluRs
(Bianchin et al., 1994; Riedel, 1996) are necessary
for memory consolidation. This is true both in the
hippocampus for aversive tasks and in the dorsal
striatum for water-maze learning (Packard et al.,
2001). The need for AMPA and mGluRs in
consolidation extends much longer than that of
NMDA receptors, as shown by the infusion of the
AMPA receptor antagonist CNQX, the a non-
NMDA receptor antagonist DNQX, MCPG
(t-methyl-4-carboxy-phenylglycine) or the mGlu
receptor antagonist dl-amino-3-phosphonopropionic
acid (AP3), respectively, into CA1, basolateral
amygdala, and entorhinal, parietal or cingulate
cortex after one-trial avoidance learning (Bonini et
al., 2003). AMPA receptors containing the GIuR2
subunit are critical for stimulus-reward learning in
mice (Mead & Stephens, 2003). In the nematode,
Caenorhabditis elegans GLR-1, a homolog of
mammalian non-NMDA receptors appears to be
critical for long-term memory formation as well
(Rose et al., 2003). Experiments using DNQX and
MCPG have shown that both receptor types are
crucially involved in the retrieval of inhibitory
avoidance in CA1, entorhinal, parietal, and
anterior cingulate cortex (Barros et al., 2000). In
addition, hippocampal AMPA receptors are also
crucial for the recall of paired associates (Day et
al., 2003).
Discrepant results concerning the relative
importance of different mGluR subtypes in
consolidation and retrieval have been reported.
Rodrigues et al. (2002) found that mGluRs in the
lateral amygdala is necessary for fear memory
formation and for long-term potentiation (LTP).
Szapiro et al. (2001), using antagonists that are
specific to different receptor isoforms concluded
that mGluR2. 3. 4. 6 are necessary for retrieval, and
that mGluR normally plays an inhibitory role. L-
AP4, an agonist at mGluR4,6, decreases the central
action of angiotensin II, although it has no effect
of its own on acquisition, consolidation, and
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Wasiluk et al., 2002). There is no question as to
the involvement of mGluRs in memory formation
and retrieval; but doubt remains about whether
different mGluR subtypes are needed for different
tasks and/or for different interactions with other
systems involved in learning processes.
In the mid-nineties much interest was shown in
the auto-regulation of glutamatergic synapses by
the stimulation-induced release of putative retro-
grade messengers, the best studied of which was
NO. The role of hippocampal NO and other ’retro-
grade messengers’ in consolidation was first
described almost a decade ago (see review by
Medina & Izquierdo, 1995). The topic was re-
studied recently in an object-recognition task
(Pitsikas et al., 2002) using the systemic
administration of an NO donor, molsidomine. Not
surprisingly, molsidomine enhanced acquisition,
storage, and retrieval. Morphine and other opiates
(Izquierdo, 1991) impair memory when given post-
training and, in addition, induce state dependency
of aversive tasks. Interestingly, Khavandgar et al.,
(2003) found that the NO synthase substrate,
L-arginine, reverses the retrograde amnesia
induced by morphine, whereas the NO-synthase
blocker, L-nitroarginine, restores the retrograde
amnesia induced by morphine in an inhibitory
avoidance task.
NEUROTROPHIC FACTORS
The results of recent studies have indicated
that neurotrophic factors are important for memory
consolidation and recall. One study (Walz et al.,
2000) showed a marked enhancement of consoli-
dation of one-trial avoidance by the intra-hippo-
campal infusion of nerve growth factor (NGF); the
effect correlated with increased ERK activity near
the site of infusion. Two studies (Alonso et al.,
2002a,b) have shown that brain-derived neuro-
trophic factor (BDNF) is critically involved in
both the formation of short-term and the long-term
memory of one-trial avoidance in the rat, also via
the activation of the MAPK pathway in the
hippocampus. Noteworthy is that short-term and
long-term memory use parallel but largely
independent biochemical systems in the hippo-
campus involving ERK (Izquierdo et al., 1999;
Izquierdo et al., 2002; Rosatto et al., 2003).
One study (Johnston & Rose, 2001) concluded
that inhibitory avoidance in the 1-day old chick
apparently depends on BDNF but not NGF.
Izquierdo et al. (2002) commented on discrepancies
between metabolic changes related to inhibitory
avoidance in adult rodents and in the day-old
chick. A problem with the latter is that the animals
were tested when they were twice the age that they
were upon training.
GENE EXPRESSION AND PROTEIN SYNTHESIS
For years, memory consolidation of many tasks
has been known to require protein synthesis in the
hippocampus. Matthies (1989) demonstrated that
RNA and protein synthesis occurs twice after a
training session, first shortly after acquisition and
then again 3 to 6 h later, and that both ’waves’ are
necessary for consolidation. This point was
recently re-examined by Igaz et al. (2002), who
found that not only protein synthesis but also gene
expression is needed at those two critical periods.
The authors used the time-honored protein
synthesis inhibitor, anisomycin, and two different
inhibitors of RNA polymerase II, DRB (5,6-
dichloro-l-13-d-ribofuranosyl benzimidazole) and
z-amanitin introduced into the hippocampus at
different times after training at doses previously
found to inhibit protein synthesis and gene
expression effectively, respectively.
Certain authors have observed the effects of
actinomycin D on memory, ascribing them to the
inhibition of gene expression. Although such
inhibition is an effect of the drug, it was shown
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necrotic lesions in the brain areas into which it is
injected (Wetzel et al., 1976) and therefore is not
recommended. DRB and ct-amanitin are to be
preferred. Here we will i;nore papers involving
localized microinfusions of actinomycin D, for
obvious reasons.
Single-based gene studies provide evidence for
the involvement of certain genes in different stages
of the acquisition and consolidation of one-trial
forms of fear conditioning. The list includes c-fos
(Cammarota et al., 2000), BDNF (Hall et al., 2000;
Alonso et al., 2002), zif268 (Hall et al., 2000), and
C/EBP (Taubenfeld et al., 2001). A number of
recent papers have focused attention on gene
profiling using eDNA arrays. Fear conditioning
increases the expression of several genes in the
hippocampus, including those coding for
tx-CaMKII, protein kinase B, ERK2, syntaxin 1A,
mGluR7, dopamine receptor 1A, the neurotrophic
receptor TRKB, and the synaptic protein homer
(Igaz et al., 2004) nurr-1, ct-actinin, and 16c8
(Ressler et al., 2002). Water maze learning
increases or decreases the expression of a host of
other genes (Cavallaro et al., 2002). The results are
somewhat irregular and different authors have
found that the activation of different genes
depends on the task and on the time at which gene
expression is measured. This field is clearly in its
beginnings, and the arrays used so far are not
sensitive enough to detect subtle and possibly
important changes.
The mapping of areas and species in which
learning is associated with protein synthesis (and/
or sensitivity to anisomycin) has been enlarged in
recent years. Auditory discrimination in gerbils is
sensitive to anisomycin given into the auditory
cortex (Kraus et al., 2002). The early consolidation
of lever pressing for food is blocked by anisu-
mycin given into the nucleus accumbens
(Hernndez et al., 2002). The inhibition of mono-
ADP-ribosylation prevents the long-term consoli-
dation of one-trial avoidance in day-old chicks
(Edwards & Rickard, 2002). Protein synthesis in
the brain of the medaka fish is necessary for fear
conditioning (Eisenberg et al., 2003).
Time windows ofmemory sensitivity to aniso-
mycin, long known in mammals, have just been
described in the sea slug Hermissenda: these time
windows are different (Epstein et al., 2003) and
differ from those of hippocampal LTP (Izquierdo
& Medina, 1997) which, in turn, differ from those
of the hippocampus in consolidation (Matthies,
1989; Rose, 1995; Igaz et al., 2002). To begin
with, in Hermissenda, the waves of protein
synthesis are multiple and quicker; in LTP the
protein synthesis wave appears to be just one. This
observation further illustrates the differences
between consolidation mechanisms across species
and brain areas, and between consolidation
mechanisms and LTP (Izquierdo & Medina, 1997;
Izquierdo & McGaugh, 2000; Izquierdo et al., 2002).
Hensbroek et al. (2003) have now reported that
spatial, contextual and working memory, all known
to depend on the hippocampus, are unaffected by
the absence of mossy fiber LTP. The mossy fiber-
CA3 connection is the gateway to the participation
of CA1 and its projections in memory (Izquierdo
& Medina, 1997). Gone are the days in which LTP
and memory were used as synonyms. Both reflect
neural plasticity, but each type of LTP and each
form of learning involves mechanisms of its own;
some may be similar, others clearly are not.
Actually, to be effective certain mechanisms that
are crucial for memory formation, like those in the
entorhinal cortex and elsewhere, probably have to
be different from those of LTP (Ardenghi et al.,
1997; Rosatto et al., 2003).
Extinction also requires protein synthesis and
gene expression in selected brain structures"
the hippocampus and the basolateral amygdala
for fear conditioning (Vianna et al., 2001,
2003a,b), and
the basolateral amygdala (Bahar et al., 2003)
and the insular cortex (Berman & Dudai, 2001)
for conditioned taste aversion.166 IV,,idq IZQUIERDO ET AL.
Peripherally administered anisomycin is
sufficient for the inhibition of memory consoli-
dation but not necessarily for the inhibition of
extinction (Lattal & Abel, 2001), suggesting that
the need for protein synthesis is higher in consoli-
dation than in extinction (Vianna et al., 2003).
Different from consolidation, extinction needs just
one peak of gene expression and protein synthesis
at the time of the first test trial without reinforce-
ment; 3 h later, DRB and anisomyein are ineffective
(Vianna et al., 2003).
Sometimes the infusion of anisomycin into the
amygdala (Nader et al., 2000; Nader, 2002), into
the hippocampus (Vianna et al., 2001; Debiec et
al., 2002), or systemically (Milekic & Alberini,
2002) at the time of retrieval can hinder retrieval
in a subsequent test session. This phenomenon is
not always seen (Vianna et al., 2001), but some-
times is seen using PKA or ERK inhibitors that are
given in the hippocampus (Szapiro et al., 2003).
Such interference has been attributed to the
reconsolidation of the original memory by
presenting the CS alone. The phenomenon is, as
mentioned, not always reproducible and has been
denied by certain authors (Myers & Davis, 2002).
Every time that behavioral testing was carried out
beyond the second test, a recovery from the
retrieval dip of the second test and an inhibition of
extinction was observed; so the dip might be just a
performance effect (Vianna et al., 2001; Szapiro et
al., 2003; Vianna et al., 2003; Lattal & Abel,
2004). The observation that retrieval makes
memory labile and susceptible to change by, for
example, the presentation of novelty (Izquierdo et
al., 2000, 2003) or, as lawyers have known for
centuries, a leading question, does not necessarily
imply reconsolidation but rather a new
consolidation process incorporating new data into
prior memory. The effect of novelty on retrieval
was studied pharmacologically and biochemically.
The effect depends on PKA and ERKs (Viola et
al., 2000). Further studies are desirable on the
purported reconsolidation process involving the
use of drugs or other variables that may effectively
enhance responses in subsequent tests. So far, the
postulation of reconsolidation in its present form
(e.g., Nader, 2002) resides only in the inconstant
effect of anisomycin given at the time of the first
of two retention tests on performance in the
second test but not in subsequent tests (Vianna et
al., 2001; Lattal & Abel, 2004). This evidence is
not sufficient to support the notion implied by the
word ’reeonsolidation’.
Exactly which proteins are synthesized in the
two peaks that follow the original training or in the
single peak that is needed for extinction is not
known. Evidence obtained in many studies after
one-trail avoidance in the day-old chick (Rose,
1995) and in a similar and other tasks in rodents
(Sandi et al., 2003) indicate that glyco- and glyco-
sialo-proteins related to cell adhesion are
synthesized by neurons that have recently
participated in memory formation, apparently also
in two waves. One of the best-known cell adhesion
proteins whose synthesis is increased post-training
and which is necessary for long-term consolidation
is the neural cell adhesion molecule (NCAM)
(Rose, 1995). The NCAM has been recently
reported to be an alternative signaling receptor for
ligands of the GDNF (glial cell line-derived
neurotrophic factor) family (Paratcha et al., 2003).
The GDNF is involved in neurite branching and
regeneration, both of which are believed to play a
role in long-term memory (Geinisman et al., 2001).
The exact role of GDNF in learning and memory,
however, has not been investigated.
ENZYME INHIBITORS AND CRITICAL
PERIODS FOR PROTEIN SYNTHESIS
The two peaks of gene expression and protein
synthesis necessary for consolidation and the peak
necessary for extinction are accompanied by
enhanced activity of PKA and by increased levels
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transcription factor, CREB (Bemabeu et al., 1997;
Taubenfeld et al., 1999). Simultaneously with
those peaks of activity, memory becomes
especially sensitive to PKA and ERK (MAPK)
inhibitors in the hippocampus (see Izquierdo &
McGaugh, 2000). The CREB protein is a substrate
of PKA, of the ERK pathway (which also becomes
activated at the time of the second peak
(Cammarota et al., 2000), and of other kinases (Wu
et al., 2001). When phosphorylated at 33Ser, CREB
triggers the transcription of various genes, some of
which are believed to be important for the fixation
of long-term memory, as well as for the
persistence of LTP beyond 3 or 4 hours (see
Izquierdo & McGaugh, 2000). Behavioral training
in one-trial avoidance increases p-CREB levels not
only in the nucleus ofhippocampal pyramidal cells
(Bemabeu et al., 1997) but also in synaptic mito-
chondria (Bevilaqua et al., 2001). In the nucleus,
downstream of CREB, the CCAAT enhancer-
binding protein (C/EBP) is also induced; it
colocalizes with p-CREB and accompanies long-
term memory consolidation (Taubenfeld et al.,
2001), for which it is also necessary. A recent
intriguing paper suggests that the ERK pathway
might be correlated with the temporal integration of
stimuli in the hippocampus (Selcher et al., 2003).
In areas other than the hippocampus, the ERK
inhibitors, U0126 and PD098059, and the PKA
inhibitors, Rp-cAMPs and KT-5720, are amnesic
as well, but post-training intervals are different
from those in the hippocampus (Ardenghi et al.,
1997; Rosatto et al., 2003). Such disparity strongly
suggests that PKA and ERK in other structures
(basolateral amygdala, entorhinal cortex, posterior
parietal, anterior cingulate cortex) are as necessary
for memory consolidation as they are in the
hippocampus but follow in them a time course of
activation that is quite different from that observed
in the hippocampus, and also quite different from
that observed in LTP. A dual peak of PKA
activity, ascertained by the action of the inhibitor,
Rp-cAMPs, and the stimulant, Sp-cAMPs, has
been described in a form of aversive leaming in
the crab Chasmagnams; the timing of the peaks is
different from that of avoidance learning in
mammals (Locatelli et al., 2002).
The role ofERKs in the hippocampal circuitry
previously described for one-trial avoidance (Walz
et al., 1999a,b) was now observed in an object
recognition task (Kelly et al., 2003) and in long-
term spatial memory (Hebert & Dash, 2002). In
one-trial avoidance, the activity of p42 and p44
increases both after training (Cammarota et al.,
2000; Alonso, 2002) and after testing (Szapiro et
al., 2000).
Two other enzymes of the MAPK family have
also been investigatednthe c-Jun N-terminal kinase
(JNK), and p38MAPK. The intra-CA1 infusion of
SP600125, the newly developed inhibitor of JNK,
at a dose that reduces c-Jun phosphorylation without
affecting ERK1/2 or p38MAPK activity, enhances
short-term memory but blocks long-term memory
formation and the retrieval of one-trial avoidance
in rats (Bevilaqua et al., 2003). Aside from
indicating a multiple role of JNK in memory
processes, the results further underline the
dichotorny between short-term and long-term
memory for this task (Izquierdo et al., 2002). In
contrast, the post-training intrahippocampal infusion
of the specific p38MAPK inhibitor, SB203580,
inhibits both short-term and long-term memory
formation of this task; the inactive analog,
SB202474 has no effect (Alonso et al., 2003). A
role for the p38 MAPK enzyme in the cerebellar
vermis in the acquisition of eye-blink conditioning
in the rabbit has also been described (Zhen et al.,
2001).
Both PKA and th ERK ar ncessary in CA1,
the basolatral amygdala, th ntorhinal cortex,
posterior parietal, and th anterior cingulate cortex
for th rtrival of one-trial avoidanc (Barros t
al., 2000). This requirement indicates that rtrival
is not th sol province of the hippocampus, as
was once blivd (Barros t al., 2003), and that it
is far from a passive event. Retrieval requires168 IVAN IZQUIERDO ET AL.
different glutamate receptors, as mentioned above,
and two major signaling pathways. A deregulation
of the ERK pathway in Alzheimer disease has
been proposed to be at the root ofthe pathogenesis
ofthis disease (Zhu et al., 2003).
Protein kinase A and ERK are also necessary
in the hippocampus (Szapiro et al., 2003) and the
basolateral amygdala (Lu et al., 2001) for the
generation of the extinction of fear conditioning at
the time of the first unrewarded retrieval test. So
are intact NMDA receptors (Falls et al., 1992;
Szapiro et al., 2003). In addition, CaMKII is
necessary in the hippocampus for the extinction of
one-trial avoidance (Szapiro et al., 2003); in the
basolateral amygdala, the role of CaMKII in
extinction has not been investigated.
Concerning the role of amygdalar PKA
activity in consolidation and extinction, two papers
from the same laboratory suggest that in
conditioned-taste aversion, things may be different
from what has been described in one-trial avoidance
in the rat, both concerning extinction (which is
enhanced by Rp-cAMPS) and short-term memory,
which is unaffected by that drug (Koh et al.,
2003). As conditioned taste aversion appears to be
rather atypical, in the sense that it does not seem to
have the same molecular requirements for acqui-
sition and extinction as do other aversive tasks,
both in the insula (Berman & Dudai, 2001) and in
the amygdala (Bahar et al., 2003), a more thorough
and systematic study of its neural and molecular
circuitry is desirable.
The role of other enzymatic pathways in
memory has also been investigated with the use of
localized infusions of inhibitors. The involvement
of guanylyl cyclase and protein kinase G in
memory formation of one-trial avoidance in the
day-old chick has been demonstrated (Edwards et
al., 2002). The results of that study agree with a
similar observation in the hippocampus obtained
years ago in one-trial avoidance in rats (Bernabeu
et al., 1996; Izquierdo & Medina, 1997). A role for
cyclin-dependent kinase 5 (Cdk) in contextual fear
conditioning is suggested by the observation that
the infusion of its antagonist, butyrolactone I, imo
the lateral septum or the hippocampus profoundly
impairs memory of the task; importantly, a single
injection of the inhibitor into either the lateral
septum or the hippocampus blocks Cdk over the
entire lateral septum and hippocampus (Fischer et
al., 2003). This blockade appears to validate the
use of localized brain infusions of drugs as
indicative of their action over large portions of the
infused structure rather than only in the infusion
site (see Izquierdo et al., 1999).
The involvement of hippocampal phospha-
tidylinositol 3-kinase (PI3K) in fear conditioning
has been demonstrated in the amygdala (Lin et al.,
2001), where it also blocks LTP, and in the
hippocampus (Barros et al., 2001). In the hippo-
campus, the PI3K inhibitor LY294002 blocks
acquisition, short-term memory formation, long-
term memory formation, and retrieval over a wide
range of doses. These findings appear to point to
the PI3K pathway as one of the most critical for
learning and memory and it certainly deserves
further study. The PI3K pathway is also linked to
the recently demonstrated participation of calci-
neurin in memory formation (Lin et al., 2001; Lin
et al., 2003).
The molecular pharmacology of consolidation
of non-associative learning has been little studied
over the years, but the results are quite clear.
Long-term habituation learning does require
NMDA receptors, protein synthesis, and signaling
pathways in the rat hippocampus (Vianna et al.,
2000), and all those plus non-AMPA receptors and
protein phosphatase activity in the abdominal
ganglion ofAplysia (Ezzedine & Glanzman, 2003).
PHARMACOLOGY OF THE UBIQUITIN
PROTEASOME SYSTEM
The ubiquitin-proteasome system hydrolyses
residues of proteins--such as I: B, the regulatoryPHARMACOLOGY OF MEMORY 169
subunit of PKA, and the 13-amyloid peptide--that
have been used in recent cell activity (Bloom et
al., 2003) and protects against oxidative stress
(L6pez-Salon et al., 2003). This system is
defective in the brain of victims of Alzheimer
disease (L6pez Salon et al., 2000). Intracellular
protein inclusions in Alzheimer disease contain a
variant of ubiquitin, UBB+I, which while still
protective against oxidative stress, blocks protea-
some 26S and is defective for most other cellular
functions (Hope et al., 2003).
Recently, the ubiquitin-proteasome system in
the hippocampus of rats has been found to be
essential for the memory consolidation of one-trial
avoidance. Two specific proteasome inhibitors,
lactacystin and proteasome inhibitor I, given 1, 4,
or 7 h post-training, block memory consolidation
of this task completely. Hours after training,
inhibitory avoidance training results in increased
26S proteasome activity and decreased IK B in the
hippocampus. These findings indicate that protein
degradation by the ubiquitin-proteasome system in
the several hours following acquisition is as
necessary for long-term memory formation as is
protein synthesis (L6pez-Sal6n et al., 2001). No
doubt, this cell system is one of the most
interesting to be studied in relation to its precise





The major brake for the installment ofmemory
consolidation is provided by GABAA receptors at
the various regions of the brain where memories
are made (Izquierdo et al., 1992). Picrotoxin and
bicuculline have been known for years to facilitate
memory formation (for references, see Izquierdo et
al., 1992; Izquierdo & McGaugh, 2000; McGaugh
& Izquierdo, 2000). Picrotoxin, which blocks the
chloride channel of GABAA receptors, facilitates
extinction as well (McGaugh et al., 1990). Agents
that enhance or mimic the action ofGABA disrupt
memory. Tiagabine, which inhibits the transport of
GABA away from the synaptic cleft, impairs
spatial learning (Schmitt & Hiemke, 2002).
Muscimol given into the hippocampus impairs
contextual retrieval of fear memory after extinction
(Corcoran & March, 2001).
A few years ago, endogenous benzodiazepine-
like molecules were described in the brain (De
Blas & Sangameswaran, 1986), and the memory-
enhancing effect of flumazenil, an antagonist of
brain benzodiazepine receptors at the GABAA
receptor complex was described (see Izquierdo &
Medina, 1991). Aside from its use for a prompt
recovery from he.patic coma, in which endogenous
and exogenous benzodiazepines are poorly meta-
bolized (Basile, 1993), flumazenil has either not
found much therapeutic application or has not
been sufficiently studied in this connection.
Flumazenil potentiates the reversal by ondansetron
of scopolamine amnesia in spatial learning in rats
(Diez-Ariza et al., 2003). In humans, the drug
reverses midazolam-induced sedation (Girdler et
al., 2002) and enhances repetition adaptability,
believed to be downregulated by widespread
GABAergic inhibitory systems (Stephenson et al.,
2003). The importance of the GABAergic
mechanism is illustrated by the observation that a
pretraining treatment with systemic midazolam
prevents the post-training memory facilitation
caused by adrenaline, naloxone, dexamethasone,
and glucosefour agents having very different
modes of action (Quevedo et al., 2002).
Because of the widespread nature of memory
inhibition by GABAA receptors (Brioni, 1993) and
its clear physiological importance (Izquierdo et al.,
1992), and because of the relative lack of side
effects, it should be interesting to study the effect
of flumazenil in more instances ofhuman memory.
Possibly the memory deficit induced by diazepam170 IVAN IZQUIERDO ET AL.
is stronger than that induced by scopolamine: the
memory-enhancing drug, oxiracetam, can prevent
the latter but not the former (Hlinak & Krejci,
200).
Monoamines
The role of dopamine-D1, [-noradrenergic,
and 5HT-1A receptors in the hippocampus, baso-
lateral amygdala, entorhinal and parietal cortex in
consolidation (Ardenghi et al., 1997; Bevilaqua et
al., 1997; Izquierdo & McGaugh, 2000; McGaugh
& Izquierdo, 2000; Mclntyre et al., 2003; Wang &
Li, 2003) and retrieval (Barros et al., 2001)
appeared settled until very recently. In general,
dopamine-D1, 13-noradrenergic, and muscarinic
cholinergic receptors have an enhancing effect in
those structures, and 5HT-1A receptors have an
inhibitory action on memory variables. Recent
research, however, has added significant data
pointing both to the involvement ofother receptors
and of other systems.
Hale and Crowe (2002) found that the D3
dopamine receptor agonist, 7-OH-DPAT, disrupts
memory consolidation of one-trial avoidance in the
day-old chick. Bemaerst and Tirelli (2003)
reported that the D4 receptor agonist, PD168077,
facilitates memory consolidation of a similar task
in mice, which in addition attenuates the amnesic
effect of 7-HO-DPAT. Apomorphine is a drug
traditionally used to mimic dopamine effects;
recently its main metabolite was found to have
effects on memory that are be very different from
those ofthe parent compound (Picada et al., 2002)
In CA1, dopamine D1 receptor activation at 3
to 4 h after training enhances memory consolidation
through an indirect stimulation of PKA via
adenylate cyclase (Ardenghi et al., 1997), similar
to what occurs 3 to 4 h atter the induction of
hippocampal LTP. This action is shared on memory
consolidation of one-trial avoidance in rats by
13-noradrenergic receptor stimulation, and both
converge toward an enhancement of CREB phos-
phorylation and protein synthesis in the hippo-
campus (lzquierdo & Medina, 1997). Recently,
Straube and Frey (2003) found that 13-noradre-
nergic receptor activation in freely moving rats 3
to 4 h after induction helps to maintain LTP. The
use of strong and repeated tetanic stimulation can
compensate for the loss of 13-noradrenergic
activation because in the behaving rat, a stronger
training stimulus can compensate for the lack of
post-training modulatory influences. Norepinephrine
infused into the basolateral amygdala of rats
enhances the consolidation of two different forms
of contextual fear conditioning (LaLumiere et al.,
2003), as has been known in one-trial avoidance
and other tasks (see Mclntyre et al., 2003).
The enhancing effect of 13-adrenoceptors on
memory consolidation has usually been attributed
to 13 /132 receptors. Using three different 133 receptor
agonists, Gibbs and Summers (2001 a) found in the
day-old chick that in one-trial avoidance, 133
receptors are also involved. In another paper, the
same authors (Gibbs & Summers 2001b) found
that tt receptors inhibit memory consolidation,
and, in a third paper (Gibbs & Summers, 2002c),
found that t2 receptors in the basal ganglia
favorably modulate the enhancing influence of 13
and [32 receptors on consolidation. These complex
interactions among adrenoceptors should also be
studied in mammals. A significant correlation was
found between plasma free 3-methoxy-4-hydroxy-
phenylglycol, a noradrenaline metabolite, measured
after encoding an emotionally arousing story
shown in slides, and long-term retention of the
story (Southwick et al., 2003).
Similar complexities have been found to occur
with 5HT receptors. As mentioned, the activation
of 5HT1A receptors in many places in the brain
usually enhances consolidation and retrieval.
Many other 5HT receptors are found in many
places in the brain, however, and the effect of 5HT
release or of the infusion of diverse 5HT-receptor
agonists and antagonists can have several different
effects, which can physiologically interact in manyPHARMACOLOGY OF MEMORY 171
ways. Thus, the post-training infusion of 5HT into
the dorsal ventral striatum causes amnesia for one-
trial avoidance in rats but has no effect when given
into the dorsal ventral striatum (Prado-Alcal et
al., 2003). Acute tryptophan depletion leads to a
transient but marked fall of 5HT contents in
humans. Such depletion impairs episodic recall
with no effect on the magnitude or the topography
of the neural correlates of retrieval, as measured
by event related potentials in healthy human
volunteers (McAllister-Williams et al., 2002). This
effect is in direct contradiction to a previous report
from our group, in which we found no effect of
acute tryptophan depletion on memory (Shansis et
al., 2000), and explaining why is difficult, in our
laboratory, acute phenylalanine and tyrosine
depletion, which inhibits catecholamine synthesis,
did cause a transient memory deficit in humans
(Grevet et al., 2002).
Meneses (2001, 2002) thoroughly investigated
the role of 5HT1B and 5HT2A,B receptors in
memory consolidation by examining the effect of
diverse agonists and antagonists of these three
receptor types and their interactions with other
drugs (dizolcipine, scopolamine, and others). A
partial agonist at 5HT4 receptors, when given
systemically together with an anti-cholinesterase
agent, enhances place and object recognition in
rats (Lamirault et al., 2003). To say the least, the
picture concerning the possible role of 5HT1B,
5HT2A,B, and 5HT4 receptors in memory is
complex, but their interactions are important
inasmuch as they indicate that in situations like
clinical depression, in which abnormalities of
5HT-containing terminals are thought to occur
(McAllister-Williams et al., 2002), a variety of
memory changes and disturbances can be expected.
Histamine
Long-standing evidence indicates that brain
histamine plays a role in the modulation of
memory consolidation via H1 and H2 receptors
(De Almeida & Izquierdo, 1986, 1988). Recent
research suggests that such modulation involves
H3 receptors too, but the data so far are unclear.
The H3 receptor antagonist, thioperamide, given
systemically causes time-dependent retrograde
memory facilitation, with no influence on retrieval,
and in addition reverses the amnesic effect of
scopolamine (Orsetti et al., 2001). For some time
peripheral histamine has been known to be
uninvolved in memory modulation (Almeida &
Izquierdo, 1988), so presumably the role of H3
receptors must be central. A different report,
however, shows that activation of H3 receptors in
the rat basolateral amygdala by R-m-methyl-
histamine or immepip improves the consolidation
of fear memory and enhances acetylcholine
release, measured by microdialysis (Cangioli et al.,
2002). The authors had previously reported that
the H3 antagonists, ciproxifan, clobenpropit, and
thioperamide given into the basolateral amygdala
decrease spontaneous acetylcholine release and
enhance memory consolidation (Passani et al.,
2001). Such a decrease points to a possible central
site of action of H3 ligands and endorses the
possibility that histamine and cholinergic
mechanisms can interact in memory modulation.
This observation is in direct contradiction to the
data with systemic thioperamide, however.
Possibly the latter could act on a set of H3
receptors in the brain elsewhere than in the
amygdala. A role of peripheral histamine in
memory modulation was discarded years ago by
the lack of effect of the peripheral histamine
releaser, 48/80 (Almeida& Izquierdo, 1988).
Cholinergic systems
The role of central cholinergic mechanisms in
memory has attracted much attention over the past
30 years. In fact, decades ago the amnesia induced
by scopolamine was often taken as a model for
Alzheimer disease, and there was or is a choli-
nergic hypothesis of Alzheimer disease and/or of172 IVAN IZQUIERDO ET AL.
dementia in general. Recent imaging (e.g., El
Fakhri et al., 2003; Karas et al., 2003) and neuro-
anatomic findings (Hyman et al., 1990; Arriagada
et al., 1992) point, rather, to a pathology beginning
in the medial temporal lobes in Alzheimer disease
and extending to the frontal and parietal cortex.
Studies on the biochemistry of Alzheimer disease
now center on amyloid and tau protein dys-
functions (Hardy, 2003; Davis & Laroche, 2003),
sometimes in relation to ubiquitin changes (L6pez-
Sal6n et al., 2000). The more recently developed
treatments of the disease explore new targets
beyond cholinergic systems like the dopamine D2
receptor (Kemppainen et al., 2003), vaccines
(Janus, 2003; Sergeant et al., 2003), and antibodies
against 13-amyloid (Hock et al., 2003). It is beyond
the purpose of this review to analyze such
treatments; for such an analysis, the reader is
referred to the excellent recent review by Davis
and Laroehe (2003).
Enough links exist, however, between brain
cholinergic muscarinic systems and Alzheimer
pathology to warrant continued investigation ofthe
former in relation to both memory consolidation
and Alzheimer disease. Acetylcholinesterase
inhibitors are still viewed by many as the drugs of
choice for the treatment of Alzheimer disease (see
Giacobini, 2003), and they play a role in the
metabolism of the amyloid-precursor protein
(Pakaski & Kasa, 2003). Imaging studies have
measured brain acetylcholinesterase in Alzheimer
patients and found a significant reduction in the
amygdala (-33%), the hippocampus (-14%), and
the neocortex (-20%); the amygdala is known to
be a major projection of the brain cholinergic
system (Shinotoh et al., 2003). Increased
Alzheimer pathology in Parkinson disease is
related to the use of antimuscarinic drugs in the
latter (Perry et al., 2003). It is interesting to read
the twin articles by Francis (2003) and Giacobini
(2003) on the role of glutamatergic and cholinergic
transmission in Alzheimer disease, respectively.
The main source of brain acetylcholine-
containing fibers is the nucleus basalis mango-
cellularis of Meynert, whose stimulation can be
used as an US (McLin et al., 2003). Lesions of this
nucleus impair the cortical plasticity associated
with skill learning (Kilgard, 2003; Conner et al.,
2003), hereto associated with extracortical
processes. In rats, new acetylcholinesterase
inhibitors were found to reverse the spatial
cognitive impairment brought about by chronic
cerebral hypoperfusion (Xu et al., 2002) or
scopolamine (Chen et al., 2002) and to enhance
place and object recognition (Lamirault et al.,
2003). There might be a link between histamine
H3 receptors (see above) and the cholinergic
system in the nucleus basalis of Meynert: an H3
receptor blocker given into that nucleus improves
place recognition memory (Orsetti et al., 2002).
Systemically administered atropine impairs the
retrieval even of highly consolidated one-trial
avoidance in mice (Boccia et al., 2003). When
given in the hippocampus,, the amygdala, or the
entorhinal, posterior parietal, or anterior cingulate
cortex, scopolamine blocks and oxotremorine
enhances the retrieval of one-way avoidance
(Barros et al., 2001). More is known about the
brain map of cholinergic modulatory mechanisms
for retrieval than for consolidation. In comparison,
more is known about the muscarinic receptor types
involved in consolidation, at least in the rat
hippocampus. In the same task, studies using
selective muscarinic toxins have revealed that M1
and M4 are involved (Ferreira et al., 2003).
Post-training intra-amygdala scopolamine
impairs the conditioned place preference brought
about by food or by amphetamine (Schroeder &
Packard, 2002) and of avoidance learning in an
elevated T-maze, in which anxiety is the
reinforcement (De-Mello & Carobrez, 2002).
Perhaps the most creative experiments
concerning the acetylcholine regulation of memory
have been produced by Gold (2003) and his group.PHARMACOLOGY OF MEMORY 173
The authors centered their approach in measuring
acetylcholine release by microdialysis in different
areas ofthe brain in relation to memory tasks known
to be dependent on those areas or on others. The
investigators found that the diencephalic damage
caused by pyrithiamine-induced thiamine deficiency
reduced the release of hippocampal acetylcholine
during spontaneous alternation, a task known to
depend on the hippocampus (Savage et al., 2003).
Gold and colleagues observed changes in the pattern
of hippocampal and striatal acetylcholine release
when rats in a cross maze were switched from
learning on the basis of place (using distant cues) to
learning on the basis ofresponse (choosing between
turning left or right to find the food). Learning in the
space mode was initially accompanied by a larger
release ofthe transmitter in the hippocampus than in
the striatum (Chang& Gold, 2003).
Mclntyre et al. (2002) found that acetylcholine
release in hippocampus correlates negatively with
good performance in an amygdala-dependent task
(food-conditioned place preference), indicating
competition between memory systems. Subsequently,
Mclntyre et al. (2003) observed cooperation
between memory systems: acetylcholine was
increased in the amygdala during spontaneous
alternation, a classic hippocampus-dependent task.
The switches--competition and cooperation between
memory systems tasks--illustrate the complex
interactions that can take place among these systems
(Gold, 2003).
The medial septal nucleus is a site of action
for the memory-stimulating effects of oxotre-
morine and the amnesic effect of scopolamine (see
Izquierdo et al., 1992). Pregnenolone given into
this area increases aeetyleholine release in the
hippoeampus and improves recognition memory in
rats (Damaudery et al., 2003).
Working memory was hitherto supposed to be
regulated mainly by the prefrontal cortex (Gold-
man-Rakie, 1996) and, at least in part, by the
hippoeampus (Olton, 1985). Two recent papers
using cholinergic muscarinic agonists/antagonists
have clearly shown that a mechanism involving
such receptors regulates working memory in the
basolateral amygdala (Beninger et al., 2001;
Barros et al., 2002).
A very interesting study showed that
scopolamine induces a time- and dose-dependent
recovery of an extinguished one-trial inhibitory
avoidance response, even month after training
(Roldq et al., 2001; see also Prado-Alcalfi, 1995).
This result of course supports the idea that
extinction is a new learning that does not erase the
original response, and in addition provides the first
pharmacological clues about the transmitters
involve in this recovery.
The purportedly antiepileptic GABAergic
compound, gabapentin, which was recently shown
to be anxiolytic (De-Paris et al., 2003), was found
to improve memory consolidation in mice through
a central muscarinic mechanism. Its memory-
enhancing effect was enhanced by physostigmine
but not by neostigmine and prevented by atropine
but not by methylatropine, mecamylamine, or
hexamethonium (B0ccia et al., 2001). The effect
was not found in rats using similar or higher doses
of gabapentin (De-Paris et al., 2000).
The November 2003 issue of Neurobiology of
Learning and Memory was dedicated to acetyl-
choline and brain functions. Of the many interesting
articles therein, perhaps the most heuristic are those
by Gold (2003), Power et al. (2003), and
Weinberger (2003). The latter is of particular
importance because it supports a role for central
nicotinic cholinergic mechanisms in the expansion
of auditory cortical auditive receptive fields upon
Pavlovian conditioning. In the same issue,
Disterhoft and Oh (2003) produce good evidence
that muscarinic receptors in the hippocampus
positively modulate their excitability in trace eye-
blink conditioning. Rogers and Kesner (2003)
show a role of muscarinic receptors in the encoding
and retrieval ofa modified Hebb-Williams maze.174 IV.N IZQUIERDO ET AL.
The endocannabinoid system Bombesin
The discovery, first of receptors for canna-
binoids and then of endogenous ligands for these
receptors, spurred much interest in the behavioral
effects of such compounds in recent years. The
main endogenous receptor for the cannabinoids is
called CB1 and is widely distributed all over the
brain. The main endogenous ligand is anandamide
(see Wilson & Nicoll, 2002; Vianna et al., 2003
for references), but there are others, including one
that is antagonistic at the CB receptor (Porter et
al., 2002). The deleterious effects of cannabinoids
on learning and memory processes was first
described by Orsingher and Fulginiti in 1970, and
recently confirmed by Mishima et al. (2001).
The deficit of spatial learning caused by delta
9-tetrahydrocannabinol is blocked by the specific
CB antagonist, SR241716A (Da & Takahashi,
2002). Anandamide impairs memory consolidation
of one-trial avoidance in mice; pre-exposure to the
apparatus reduces the effect. The drug has no
effect upon retrieval when given before testing
(Costanzi et al., 2003).
The most important recent finding concerning
the endogenous cannabinoid system and memory
is the demonstration that this system, probably in
the basolateral amygdala, controls the extinction of
aversive conditioned responses in the rat (Marsi-
cano et al., 2002). This aspect should now be
studied in relation to the signaling pathways found
to regulate extinction in the amygdala and else-
where (see Vianna et al., 2003a, b). The amygdala
is characterized by a large presence of CB1
receptors, which appear to be in control of local
GABAergic transmission (Katona et al., 2001).
The CB1 cannabinoid system has also been
proposed to play a role in the endogenous defense
against excitotoxocity (Marsicano et al., 2003), in
the induction ofLTP (Carlson et al., 2002), and in
the mediation of retrograde signaling in the
hippocampus (Wilson & Nicoll, 2001).
One paper shows that the intrahippocampal
infusion ofRC-3095, the bombesin/gastrin-releasing
peptide antagonist, impairs inhibitory avoidance in
rats (Roesler et al., 2003). The drug was effective
when given immediately or 2 h after training. This
finding suggests the presence of receptors for
bombesin in the hippocampus, and that these are
able to regulate memory consolidation for a long
time after training.
Memory modulation by glucose
Memory modulation by glucose was discovered
by Gold (1986) and then investigated by his group
and by many others (eg. Sunram-Lea et al., 2002;
Metzger & Flint, 2003). More recently, Gold’s
group when measuring extracellular brain glucose
observed that the level of extracellular fluid
glucose in the brain is much lower than previously
thought and fluctuates widely across brain areas
during testing. The extracellular glucose levels
decrease by 30% in the hippocampus and increase
by 9% in the striatum during spontaneous alter-
nation (McNay et al., 2001). Further, extracellular
hippocampal glucose levels decrease with aging: at
the age of 3 months in rats, those levels tend to
accompany circulating glucose levels but reverse
at the age of24 months (McNay & Gold., 2001).
Systemic or intra-amygdala glucose injections
facilitate onset of the extinction of drug-induced
conditioned reward (Schroeder & Packard, 2003).
In the day-old chick inhibitory avoidance model,
glucose enhances, and the glucose-uptake inhibitor
2-deoxyglucose disrupts memory consolidation.
Using 132 and 133 adrenoceptor blockers, Gibbs and
Summers (2002) concluded that the latter receptor
subtype could facilitate glucose uptake by brain
cells at the time of consolidation. Talley et al.
(2002) observed that vagotomy attenuates the
enhancement effect of glucose on spontaneousPHARMACOLOGY OF MEMORY 175
alternation. This point is of interest on two counts.
First, the effect of glucose on that task, believed to
be regulated almost exclusively by the hippo-
campus. Second, the suggestion that the glucose
effect can be mediated by vagal afferents, such as
studied 45 years ago in connection with the
regulation ofblood pressure (Izquierdo et al., 1959).
STRESS AND MEMORY
Memory consolidation and retrieval have been
known for a long time to be regulated by
circulating levels of stress hormones (Izquierdo,
1989). A lot of work has been done in the past 2
years on this topic. The epinephrine enhancement
ofhuman memory consolidation occurs through an
interaction with arousal at the time of encoding
(Cahill & Alkire, 2003). Possibly other stress
hormones like corticoids, adrenocorticotropin,
vasopressin, 13-endorphin (see Izquierdo, 1989)
can act similarly. Long ago, Gold and McGaugh
(1975) proposed that endogenous stress hormones
modulate memory consolidation for experiences
that induce their release. Subsequently, Izquierdo
(1989) produced evidence showing that these
substances actually induce a form of endogenous
state dependency for the tasks that released them,
or for the effect oftheir systemic administration.
Glucocorticoids have opposite effects on
consolidation, which they regularly enhance, and on
retrieval, which they consistently impair
(Roozendaal, 2002; McAllister-Williams & Rugg,
2002; Hsu et al., 2003). The consolidation effect is
due to an interaction with a 13-adrenoceptor
mechanism in the basolateral amygdala involving
activation of a cAMP/PKA system (Roozendaal et
al., 2002). The action of glucocorticoids upon
retrieval probably involves the hippocampus
(Roozendaal et al., 2001; Jezek et al., 2002) with an
involvement of the amygdala (Roozendaal et al.,
2003) and is accompanied by reduced blood flow in
the medial temporal lobe (de Quervain et al., 2003).
Whereas the influence of glucocorticoids or
other stress hormones facilitates memory
formation for traumatic or otherwise aversive
experiences (Cordero et al., 2002), the influence of
glucocorticoids at the time of retrieval prevents
recall of such experiences and therefore protects
from the possible development of post-traumatic
stress disorder(s) (Schelling, 2002). Chronic and
repeated stress causes hippocampal cell death from
the actions of glucocorticoids at their receptors
(Sapolsky, 2001); this exacerbation of local
toxicity is not caused by apoptosis (Roy &
Sapolsky, 2002).
Stress experience and age determine the
impairing or enhancing effects of stress and
corticoids on retrieval (Yang et al., 2002).
Recently we studied the effect of four different
stress hormones, ACTH, adrenaline, vasopressin,
and 13-endorphin on the retrieval of one-trial
avoidance in rats, measured at day or at 3 to 19
months after training--that is, when both memory
and animals were young, middle-aged, and old
(Izquierdo et al., 2002). The animals were trained
at the age of 3 months. When given before testing,
all four drugs facilitated retrieval. The doses
needed day after training were lower than at 3
months. Between 6 and 9 months, the effect of the
four hormones changed into a negative influence:
all four depressed retrieval. Yet, in animals tested
12 to 19 months after training at the younger age,
retrieval again became gradually more and more
sensitive to the drugs, and at the oldest age (22
months) and training-test interval (19 months),
retrieval was as sensitive to the facilitator effect of
the hormones as it was at the age of3 months. This
finding suggests a strong bimodal response of
retrieval mechanisms to age and/or training-test
intervals and may be related to the higher
emotionality and retrieval of emotional responses
seen in the young and the old, as compared with
middle-aged humans.176 IVAN IZQUIERDO ET AL.
Vasopressin has long been known to enhance
both memory consolidation and retrieval in rodents
(see above and Paban et al., 2003). The effect on
consolidation has not always been reproduced in
humans, as a recent failed attempt attests (Gais et
al., 2002), making it somewhat different from
other stress hormones (see Cahill & Alkire, 2003).
NON-CORTICOID-STEROID HORMONE
EFFECTS ON MEMORY
The effect of androgens and estrogens on
memory has been comparatively little studied over
the years. Recently, Johnston and Migues (2001)
found a task- and time-dependent memory
enhancement by dehydroepiandrosterone in a visual
categorization task and in one-trial avoidance in
the day-old chick. The substance is normally
present in the chick brain, which makes the result
even more interesting. Androgens given post-
training to ovariectomized rats enhance the memory
of a Y-maze, inhibitory avoidance, and object
recognition; the effect is unrelated to changes in
affective behavior caused by the hormones (Frye
& Lacey, 2001).
In rats, estrogens quickly enhance visual and
place memory in rats (Luine et al., 2003). The
finding is consistent with that of Chen et al.,
(2002) who observed that the two antiestrogen
agents tamoxifen and toremifene (widely used for
the treatment of breast cancer) impair memory in
appetitive and aversive several tasks in mice. It
would be interesting to know whether the actions
of estrogens on memory involve the recently
described G-protein-coupled receptor implied in
rapid signaling involving protein kinase C in the
hypothalamus (Qin et al., 2003). Pregnenolone and
other neurosteroids have been proposed to be
biomarkers of ’cognitive aging’ (Vallee et al.,
2003). As mentioned above, pregnenolone acts on
the medial septum to improve recognition memory
(Darnaudery et al., 2002).
STATE DEPENDENCY
The concept of endogenous state dependency
was formulated twenty years ago (Izquierdo, 1984,
1989). The hypothesis is based on the principle
that the prevalence of neurohumoral and hormonal
states at the time of retrieval similar to those that
existed in the post-training period is a key factor in
retention test performance. Numerous experiments
have endorsed this proposal.
Recently, the concept was retaken by Colpaert
and his group, who enlarged it to the point that,
according to their formulations and supporting
findings, mnesic states actually govern both normal
and disordered memory (Colpaert et al., 2001).
This notion would apply not only to opioid-
addiction states (Bruins Slot et al., 2001) but also
to the lack of full reversal of the amnesic effect of
scopolamine by tacrine (Bruins Slot et al., 2003).
This approach is interesting and it might explain
the hitherto obscure aspects ofmemory retrieval.
To reexamine the recent proposal by Summers
et al. (2003) of two consecutive processes in
retrieval might be useful, in light of not only the
concept of endogenous state dependency
(Izquierdo, 1984; Colpaert et al., 2001) but also
the findings on the molecular pharmacology of
retrieval (Barros et al., 2000, 2001, 2003). Enough
evidence might not be available to sustain the
dual-process hypothesis of retrieval, which is a
pity because the hypothesis is sound and worth
further exploration.
EXTINCTION: ITS THERAPEUTIC ROLE AND
CAN IT BE ENHANCED?
Acquired fear is at the root of phobias, panic
attacks, generalized anxiety, posttraumatic stress
disorder, and at least some forms of depression,
including that of bipolar disorders (Lee et al.,
2002; Beckett, 2002; Rothbaum & Schwartz,
2002). It thus appears as a therapeutic desideratumPHARMACOLOGY OF MEMORY 177
to inhibit conditioned fear in these patients.
Extinction has been for 80 years the therapy of
choice for the treatment of psychiatric problems
caused by acquired fear (Cammarota et al., 2003;
Paquette et al., 2003). Therapies involving
extinction are sometimes called habituation,
exposure, or flooding therapies, but in essence, all
consist of repeated exposure to the stimuli that had
been conditioned to represent fear by previous
training, but now in the absence of reinforcement.
Several sources of failure in the therapy of
conditioned fear have been reported; these have
been recently revised by Bouton (2002). Care must
be taken to promote extinction and to avoid the
reinstatement of the original fear (Cammarota et
al., 2003).
Often extinction or exposure therapies are
complemented by benzodiazepines, seen by some
(Harris & Westbrook, 1999) as extinction
enhancers, or by other drugs, like propranolol,
which has been used for years to attenuate anxiety
at the time of retrieval or performance. Recently, a
nonpharmacologic enhancement of extinction has
been obtained in rats merely by increasing the time
spent by the rats in the no-reinforcement situation.
Animals were trained in a standard one-way
inhibitory procedure, using a platform as the CS
and a footshock delivered to a grid as the US. In
extinction sessions, the footshock was not
delivered; but instead of withdrawing the animal
from the training apparatus, as is usually done (eg.,
Vianna et al., 2003), the animals were allowed to
explore the grid freely for 30 seconds with no
footshock. Under such conditions, extinction was
stronger, and to reinstall the original conditioned
response in a fifth extinction session, the animals
required gene expression and protein synthesis"
recovery of the original learning was blocked by
DRB and anisomycin (Cammarota et al., 2003) as
if the task were new (Igaz et al., 2002). Devising
many ways in which such an enhanced exposure to
the absence of the US can be applied to human
therapy situations is possible.
FINAL COMMENT
Major advances have been made in the past 2
or 3 years on the biochemical pharmacology of
memory, retrieval, and extinction. Nevertheless,
we are still far a long away from understanding the
intimate nature ofmemory, retrieval, and extinction.
The key question of what memory consolidation,
retrieval, and extinction really are about has not
yet been answered. To show that one or other
housekeeping neurotransmitter(s) or enzyme(s) are
involved in consolidation, extinction or retrieval at
different times is not the same as showing their
intimate nature, as believed around 3 years ago.
Studies on differential gene activation by learning
tasks have so far been disappointing. The multitude
of new findings in the area of the molecular
mechanisms of memory might give us reasons to
rejoice but not yet celebrate a genuine
breakthrough.
We apologize to the authors of the perhaps
many significant papers that came out during the
past 2 or 3 years in the subjects reviewed and were
not included here; but then, that is the lot of
reviews. They are always bound to be incomplete.
REFERENCES
Alonso M, Bevilaqua LR, Izquierdo I, Medina JH,
Cammarota M. 2003. Memory formation requires
p38 MAPK activity in the rat hippocampus.
Neuroreport 14: 1989-1992.
Alonso M, Vianna MR, Depino R, Mello e Souza T,
Pereira P, et al. 2002. BDNF-triggered events in
the rat hippocampus are required for both short-
and long-term memory formation. Hippocampus
12:551-260.
Alonso M, Vianna MR, Izquierdo I, Medina JH
2002. Signaling mechanisms mediating BDNF
modulation of memory formation in vivo in the
hippocampus. Cell Mol Neurobiol 22: 663-674.
Alonso M, Viola H, Izquierdo I, Medina JH. 2002.
Aversive experiences are associated with a rapid
and transient activation of ERKs in the rat
hippocampus. Neurobiol Learn Mem 77:. 119-124.178 IVAN IZQUIERDO ET AL.
Ardenghi P, Barros DM, Izquierdo LA, Bevilaqua L,
Schr6der N, Quevedo J, et al. 1997. Late and
prolonged post-training memory modulation in
entorhinal and parietal cortex by drugs acting on
the cAMP/protein kinase A signalling pathway.
Behav Pharmacol 8: 745-751.
Arriagada PV, Growdon JH, Hedley-Whyte ET,
Hyman BT. 1992. Neurofibrillary tangles but not
senile plaques parallel duration and severity of
Alzheimer’s disease. Neurology 42: 631-639.
Bahar, A, Anat, S, Dudai Y. 2003. The amygdalar
circuit that acquires taste aversion memory differs
from the circuit that extinguishes it. Eur J
Neurosci 17" 1527-1530.
Barros DM, Izquierdo LA, Mello e Souza T,
Ardenghi P, Pereira P, et al. 2000. Molecular
signalling pathways in the cerebral cortex are
required for retrieval of one-trial avoidance
learning in rats. Behav Brain Res 114: 183-192.
Barros DM, Izquierdo LA, Medina JH, Izquierdo I.
2003. Pharmacological findings contribute to the
understanding of the main physiological
mechanisms of memory retrieval. Current Drug
Targets: CNS & Neurol Disorders 2" 81-94.
Barros DM, Mello e Souza T, De David T, Choi T,
Aguzzoli A, et al. Simultaneous modulation of
retrieval by dopaminergic DI, [3-noradrenergic,
serotoninergiclA and cholinergic muscarinic
receptors in cortical structures of the rat. Behav
Brain Res 2001.124" 1-7.
Barros DM, Mello E, Souza T, de Souza MM, Choi
H, DeDavid E, et al. 2001. LY294002, an
inhibitor of phosphoinositide 3-kinase given into
rat hippocampus impairs acquisition, consolidation
and retrieval of memory for one-trial inhibitory
avoidance. Behav Pharmacol 12: 629-634.
Barros DM, Pereira P, Medina JH, Izquierdo. 2002.
Modulation of working memory and of long- but
not short-term memory by cholinergic mechanisms
in the basolateral amygdala. Behav Pharmacol 13"
163-167.
Basile AS. 1993. The role ofbenzodiazepine receptor
ligands in the pathogenesis of hepatic encephalo-
pathy. In: Izquierdo I, Medina JH, eds, Natural
Occurring Benzodiazepines: Structure, Distribution
and Function. London, UK: Ellis Horwood; 89-114.
Beckett WS. 2002. Post-traumatic stress disorder.
New Engl J Med 346: 1495-1498.
Beninger RJ, Dringenberg HC, Boegman RJ,
Jhamandas K. 2002. Cognitive effects of
neurotoxic lesions of the nucleus basalis mango-
cellularis in rats: differential roles for corticopetal
versus amygdalopetal projections. Neurotox Res
3: 7-21.
Berman DE, Dudai Y. 2001. Memory extinction,
learning anew, and learning the new: dissociations
in the molecular machinery of learning in cortex.
Science 2001.291’ 417-2419.
Bernabeu R, Bevilaqua L, Ardenghi P, Bromberg E,
Schmitz M, Bianchin M, et al. 1997. Involvement
of hippocampal D1/D5 receptor-cAMP signaling
pathways in late memory consolidation. Proc Natl
Acad Sci USA 94: 7041-7046.
Bernabeu R, Schmitz P, Faillace MP, Izquierdo I,
Medina JI-I. 1996. Hippocampal cGMP and
cAMP are differentially involved in memory
processing of an inhibitory avoidance learning.
Neuroreport 7: 585-588.
Bernaerst P, Tirelli E. 2003. Facilitatory effect of the
dopamine D4 receptor agonist PD168077 on
memory consolidation of an inhibitory avoidance
learned response in C57BL/6J mice. Behav Brain
Res 142:41-52.
Bevilaqua L, Ardenghi P, Schr6der N, Bromberg E,
Schmitz E, Schaeffer E, et al. 1997. Drugs that
influence the cyclic adenosine monophosphate/
protein kinase A signaling pathway alter memory
consolidation when given late after training into
rat hippocampus but not amygdala. Behav
Pharmacol 8:331-338.
Bevilaqua LRM, Cammarota M, Paratcha G, Levi de
Stein M, Izquierdo I, Medina JH. 1999.
Experience-dependent increase in cAMP-
responsive element binding protein in synaptic
and nonsynaptic mitochondria of the rat hippo-
campus. Eur J Neurosci 11,3753-3756.
Bevilaqua LR, Kerr DS, Medina JH, Izquierdo I,
Cammarota M. 2003. Inhibition of hippocampal
Jun N-terminal kinase enhances short-term memory
but blocks long-term memory formation and
retrieval of an inhibitory avoidance task. Eur J
Neurosci 17: 897-902.
Bianchin M, da Silva RC, Schmitz PK, Medina JH,
Izquierdo I. 1994. Memory of inhibitory
avoidance in the rat is regulated by glutamate
metabotropic receptors in the hippocampus.
Behav Pharmacol 5: 356-359.
Bloom J, Amador V, Bartolini F, DeMartino G, Pagano
M. 2003. Proteasome-mediated degradation of p21
via N-terminal ubiquitinylation. Cell 115" 71-82.PHARMACOLOGY OF MEMORY 179
Boccia MM, Acosta GB, Baratti CM. 2001. Memory
improving actions of gabapentin in mice: possible
involvement of central muscarinic cholinergic
mechanism. Neurosci Lett 311" 153-156.
Boccia MM, Blake MG, Acosta GB, Baratti CM.
2003. Atropine, an anticholinergic drug, impairs
memory retrieval of a high consolidated avoidance
response in mice. Neurosci Lett 345: 97-100.
Bonini JS, Rodrigues L, Kerr DS, Bevilaqua LR,
Cammarota M, Izquierdo, I. 2003. AMPA/kainate
and group-I metabotropic receptor antagonists
infused into different brain areas impair memory
formation of inhibitory avoidance in rats. Behav
Pharmacol 14:161-166.
Bouton ME. 2002. Context, ambiguity, and
unlearning: sources of relapse after behavioral
extinction. Biol Psychiatry 52: 976-986.
Brioni JD. 1993. Role ofGABA during the multiple
consolidation of memory. Drug Develop Res 28"
3-27.
Bruins Slot LA, Chopin P, Colpaert FC. 2003.
Tacrine-scopolamine interactions on state-
dependent retrieval. Psychopharmacology 166:
33-39.
Bruins Slot LA, Colpaert FC. 2003. A persistent
opioid-addiction state of memory. Behav
Pharmacol 14: 167-171.
Cahill L, Alkire MT. 2003. Epinephrine enhancement
of human memory consolidation: interaction with
arousal at encoding. Epinephrine enhancement of
human memory consolidation: interaction with
arousal at encoding. Neurobiol Learn Mem 19:
194-198.
Cammarota M, Bernabeu R, Izquierdo I, Medina JH.
1996. Reversible changes in hippocampal 3[H]-
AMPA binding following inhibitory avoidance
training in the rat. Neurobiol Learn Mem 66: 85-
88.
Cammarota M, Bernabeu R, Levi de Stein M,
Izquierdo I, Medina JH. 1998. Learning-specific,
time-dependent increases in hippocampal Ca2//
calmodulin-dependent protein kinase II activity
and AMPA GIuR1 subunit immunoreactivity. Eur
J Neurosci 10" 2669-2676.
Cammarota M, Bevilaqua LR, Ardenghi P, Paratcha
G, Levi de Stein M, et al. 2000. Learning-
associated activation of nuclear MAPK, CREB
and Elk-l, along with Fos production,in the rat
hippocampus after a one-trial avoidance learning:
abolition by NMDA receptor blockade. Brain Res
Mol Brain Res 76" 36-46.
Cammarota M, Bevilaqua LRM, Kerr D, Medina JH,
Izquierdo I. 2003. Inhibition of mRNA and
protein synthesis in the CA1 region of the dorsal
hippocampus blocks reinstallment of an extin-
guished conditioned fear response. J Neurosci 23"
737-741.
Cammarota M, Levi de Stein M, Paratcha G,
Bevilaqua LRM, Izquierdo I, Medina JH. 2000.
Rapid and transient learning-associated increase
in NMDA NR1 subunit in rat hippocampus.
Neurochem Res 2000. 25: 567-572.
Cangioli I, Baldi E, Mannaioni PF, Bucherelli C,
Blandina P, Passani MB. 2002. Activation of
histaminergic H3 receptors in the rat basolateral
amygdala improves expression of fear memory
and enhances acetylcholine release. Eur J
Neurosci 16: 521-528.
Carlson G, Wang Y, Alger BE. 2002. Endocanna-
binoids facilitate the induction of LTP in the
hippocampus. Nat Neurosci 5" 723-724.
Castellano C, Cestari V, Ciamei A. 2001. NMDA
receptors and learning and memory processes.
Curr Drug Targets 2: 273-283.
Cavallaro S, D’Agata V, Manickam P, Dufour F,
Alkon DL. 2002. Memory-specific temporal
profiles of gene expression in the hippocampus.
Proc Natl Acad Sci USA 99:16279-16284.
Chang Q, Gold PE. 2003. Switching memory systems
during learning: changes in patterns of brain
acetylcholine release in the hippocampus and
striatum of rats. J Neurosci 23" 3001-3005.
Chen D, Wu CF, Shi B, Xu YM. 2002. Tamoxifen
and toremifene cause impairment of learning and
memory function in mice. Pharmacol Biochem
Behav 71: 269-276.
Chen Z, Xu AJ, Li R, Wei EQ. 2002. Reversal of
scopolamine-induced spatial memory deficits inm
rats by TAK-147. Acta Pharmacologica Sinnica
23: 355-360.
Coitinho AS, Roesler R, Martins VR, Brentani RR,
Izquierdo I. 2003. Cellular prion protein impairs
behavior as a function of age. Neuroreport 14:
1375-1379.
Coitinho AS, Dietrich MO, Hoffmann A, Dall’Igna
OP, Souza DO, Martins VR, et al. 2002.
Decreased locomotion induced by MK-801, but
not amphetamine and caffeine in mice lacking180 IV/kN IZQUIERDO ET AL.
cellular prion protein (PrPC), but not amphetamine
and caffeine. Mol Brain Res 107" 190-194.
Colley PA, Routtenberg A. 1993. Long-term poten-
tiation as synaptic dialogue. Brain Res Rev 18:
115-122.
Colpaert FC, Koek W, Bruins Slot LA. 2001. Evidence
that mnesic states govern normal and disordered
memory. Behav Pharmacol 12: 575-589.
Conner JM, Culberson A, Packowski C, Chiba AA,
Tuszynski MH. 2003. Lesions of the basal fore-
brain cholinergic system impair task acquisition
and abolish cortical plasticity associated with
motor learning. Neuron 38:819-829.
Cordero M., Kruyt ND, Merino JJ, Sandi C. 2002.
Glucocorticoid involvement in memory formation
in a rat model for traumatic memory. Stress 5: 73-
79.
Corcoran KA, Maren S. 2001. Hippocampal inactiva-
tion disrupts contextual retrieval of fear memory
after extinction. J Neurosci 21" 1720-1726.
Costanzi M, Battaglia M, Populin R, Cestari V,
Castellano C. 2003. Anandamide and memory in
CDI mice: effects of immobilization stress and of
prior experience. Neurobiol Learn Mem 79: 204-
211.
Da S, Takahashi RN. 2002. SRI41716A prevents delta
9-tetrahydrocannabinol-induced spatial learning
deficit in a Morris-type water maze in mice. Prog
Neuropsychopharmacol Biol Psychiatry 26: 321-
325.
Darnaudery M, Pallares M, Piazza PV, LeMoal M,
Mayo W. 2002. The neurosteroid pregnenolone
sulfate infused into the medial septum nucleus
increases hippocampal acetylcholine and spatial
memory in rats. Brain Res 95: 237-242.
Davis M, Walker DL, Myers KM. 2003. Role of the
amygdala in fear extinction measured with
potentiated startle. AnnNY Acad Sci 985:218-232.
Day M, Langston R, Morris RG. 2001. Glutamate-
receptor-mediated encoding and retrieval of
paired-associate learning. Nature 424: 205-209.
Day M, Morris RG. 2001. Memory consolidation and
NMDA receptors" discrepancy between genetic
and pharmacologic approaches. Science 293: 755.
De Almeida MAMR, Izquierdo I. 1988. Intracerebro-
ventricular histamine, but not 48/80, causes post-
training memory facilitation in the rat. Arch Int
Pharmacodyn Ther 291: 202-208.
De Almeida MAMR, Izquierdo I. 1986. Memory
facilitation by post-training histamine administration.
Arch Int Pharmacodyn Ther 283:193-198.
Debiec J, LeDoux JE, Nader K. 2002. Cellular and
systems reconsolidation in the hippocampus.
Neuron 36: 527-538.
De Bias A, Sangameswaran L. 1986. Demonstration
and purification of an endogenous benzodiazepine
from the mammalian brain with a monoclonal
antibody to benzodiazepines. Life Sciences 39:
1927-1936.
De Leonibus E, Lafenetre P, Oliverio A, Mele A.
2003. Pharmacological evidence for the role of
dorsal striatum in spatial memory consolidation in
mice. Behav Neurosci 117: 685-694.
De-Mello N, Carobrez AP. 2002. Elevated T-maze as
an animal model of memory: effects of scopol-
amine. Behav Pharmacol 13" 139-148.
De-Paris F, Busnello JV, Vianna MR, Salgueiro JB,
Quevedo J, Izquierdo I, et al. 2000. The
anticonvulsant compound gabapentin possesses
anxiolytic but not amnesic effects in rats. Behav
Pharmacol 11:169-173.
De-Paris F, Sant’Anna MK, Vianna MR, Barichello
T, Busnello JV, Kapczinski F, et al. 2003. Effects
of gabapentin on anxiety induced by simulated
public speaking. J Psychopharmacol 17:184-188.
De Quervain DJ, Henke, Aerni A, Treyer V,
McGaugh JL, Berthold T, et al. 2003. Gluco-
corticoid-induced impairment of declarative
memory retrieval is associated with reduced blood
flow in the medial temporal lobe. Eur J Neurosci
17: 1296-1302.
Diez-Ariza M, Redondo C, Garcia-Alloza M, Lasheras
B, Del Rio J, Ramirez MJ. 2003. Flumazenil and
tacrine increase the effectiveness of ondansetron on
scopolamine-induced impairment of spatial learning
in rats. Psychopharmacology 169:35-41.
Disterhoft JF, Oh MM. 2003. Modulation of choli-
nergic transmission enhances excitability of
hippocampal pyramidal neurons and ameliorates
learning impairments in aging animals. Neurobiol
Learn Mem 80: 223-233.
Edwards TM, Rickard NS. 2002. Inhibition of mono-
ADP-ribosylation prevents long-term memory
consolidation of a single-trial passive avoidance
task in the day-old chick. Neurobiol Learn Mem
78: 192-198.
Edwards TM, Rickard NS, Ng KT. 2002. Inhibition of
guanylate cyclase and protein kinase G impairs
retention for the passive avoidance task in the day-
old chick. Neurobiol Learn Mem 77: 313-326.PHARMACOLOGY OF MEMORY 181
Eichenbaum H, Schoenbaum G, Young B, Bunsey M.
1996. Functional organization of the hippocampal
memory system. Proc Natl Acad Sci USA 93:
13500-13507.
Eisenberg M, Kobilo T, Berman DE, Dudai Y. 2003.
Stability of retrieved memory: inverse correlation
with trace dominance. Science 301" 1102-1104.
E1 Fakhri G, Kijewski MF, Johnston KA, Syrkin G,
Killany RJ, Becker JA, et al. 2003. MRI-guided
SPECT perfusion measures and volumetric MRI
in prodromal Alzheimer disease. Arch Neurol 60:
1066-1072.
Epstein HT, Child FM, Kuzirian AM, Alkon DL.
2003. Time windows for effects of protein
synthesis inhibitors on Pavlovian conditioning in
Hermissenda: behavioral aspects. Neurobiol
Learn Mem 79: 127-131.
Ezzedine Y, Glanzman DL. 2003. Prolonged habituation
of the gill-withdrawal reflex in Aplysia depends
on protein synthesis, protein phosphatase activity,
and postsynaptic glutamate receptors. J Neurosci
23: 9585-9594.
Falls, WA, Miserendino MJ, Davis M. Extinction of
fear-potentiated startle: blockade by infusion of
an NMDA antagonist into the amygdala. J
Neurosci 1992. 12" 854-863.
Fedosiewicz-Wasuluk M, Holy ZZ, Wisniewski K.
2002. L-AP4, a potent agonist of group III meta-
botropic glutamate receptor, decreases central
action of angiotensin II. Pol J Pharmacol 54: 415-
422.
Ferreira AR, Furstenau L, Blanco C, Kornisiuk E,
Schez G, Daroit D, et al. 2003. Role of hippo-
campal MI and M4 muscarinic receptor subtypes
in memory consolidation in the rat. Pharmacol
Biochem Behav 74" 411-415.
Fischer A, Sananbenesi F, Shriek C, Spiess J,
Radulovic J. 2003. Regulation of contextual fear
conditioning by baseline and inducible septo-
hippocampal cyclin-dependent kinase 5.
Neuropharmacology 44:1089-1099.
Francis PT. Glutamatergic systems in Alzheimer’s
disease. International Journal of Geriatric
Psychiatry 2003.18: S 15-$21.
Frye CA, Lacey EH. 2001. Post-training androgens’
enhancement of cognitive performance is
temporally distinct from androgens’ increases in
affective behavior. Cogn Affect Behav Neurosci
1: 172-182.
Gais S, Sommer M, Fischer S, Perras B and Born J.
2002. Post-trial administration of vasopressin in
humans does not enhance memory formation.
Peptides 23: 581-583.
Geinisman Y, Berry RW, Disterhoft JF, Power JM,
van der Zee E. 2001. Associative learning elicits
the formation of multiple-synaptic boutons. J
Neurosci 21" 5569-5573.
Giacobini E. 2003. Cholinergic function and
Alzheimer’s disease. Int J Geriatr Psychiatry 18:
S1-$5.
Gibbs ME, Summers J. 2001 a. Enhancement ofmemory
consolidation in chicks by beta(3)-adrenoceptor
agonists. Eur J Pharmacol 413: 235-240.
Gibbs ME, Summers J. 2001 b. Stimulation of alphal-
adrenoceptors inhibits memory consolidation in
the chick. Eur J Neurosci 14" 1369-1376.
Gibbs ME, Summers J. 2002. Effects of glucose and
2-deoxyglucose on memory formation in the
chick: interaction with beta(3)-adrenoceptor
agonists. Neuroscience 114: 69-79.
Gibbs ME, Summers J. 2003. Alpha 2-adrenoceptors
in the basal ganglia have a role in memory
consolidation and reinforcement. Neuropharma-
cology 45: 255-367.
Girdler NM, Lyne JP, Wallace R, Neave N, Scholey
A, Wesnes KA, et al. 2002. A randomised,
controlled trial of cognitive and psychomotor
from midazolam sedation following reversal with
oral flumazenil. Anaesthesia 57" 868-876.
Gold PE. 2003. Acetylcholine modulation of neural
systems involved in learning and memory.
Neurobiol Learn Mem 80:194-210.
Gold PE. 1986. Glucose modulation of memory
storage processing. Behav Neural Biol 45" 342-
349.
Gold PE, McGaugh JL. 1975. A single trace, dual
process view of memory storage processes. In
Deutsch D, Deutsch JA. eds, Short-Term Memory.
New York, NY, USA: Academic Press; 355-378.
Goldman-Rakic P. 1996. Regional and cellular
fractionation of working memory. Proc Natl Acad
Sci USA 93" 13473-13480.
Grevet EH, Tietzmann MRM, Shansis FM,
Hastenpflugl C, Santana LC, Forster L, et al.
2002. Behavioural effect of acute phenylalanine
and tyrosine depletion in healthy male volunteers.
J Psychopharmacol 16: 51-55.
Guti6rrez R, Tellez LA, Bermfdez-Rattoni F. 2003.
Blockade of cortical muscarinic but not NMDA
receptors prevents a novel taste from becoming182 IVAN IZQUIERDO ET AL.
familiar. Eur J Neurosci 17: 1556-1562.
Hale MW, Crowe SF. 2002. The effects of selective
dopamine agonists on a passive avoidance
learning task in the day-old chick. Pharmacology
13: 295-301.
Hall J, Thomas KL, Everitt BJ. 2000. Rapid and
selective induction of BDNF expression in the
hippocampus during contextual learning. Nat
Neurosci 3" 533-535.
Hardy J. 2003. The relationship between amyloid and
tau. JMol Neurosci 20: 203-206.
Harris JA, Westbrook RF. 1999. The benzodiazepine
midazolam does not impair Pavlovian fear
conditioning but regulates when and where fear is
expressed. J Exp Psychol Anim Behav Process
25: 236-246.
Hebert AE, Dash PK. 2002. Extracellular signal-
regulated kinase activity in the entorhinal cortex
is necessary for long-term spatial memory. Learn
Mem 9:156-166.
Hensbroek RA, Kamal A, Baars AM, Verhage M,
Spruijt BM. 2003. Spatial, contextual and working
memory are not affected by the absence of mossy
fiber long-term potentiation and depression.
Behav Brain Res 138" 215-223.
Hernfindez PJ, Sadeghian K, Kelley AE. 2002. Early
consolidation of instrumental learning requires
protein synthesis in the nucleus accumbens. Nat
Neurosci 5: 1327-1331.
Hirsh R. 1974. The hippocampus and contextual
retrieval of information from memory: a theory.
Behav Biol 12: 421-444.
Hlinak Z, Krejci I. 2002. Oxiracetam prevents the
scopolamine but not the diazepam induced
memory deficits in mice. Behav Brain Res 133:
395-399.
Hock C, Konietzko U, Streffer JR, Tracy J, Signorell
A, Mtlller-Tillmans B, et al. 2003. Antibodies
against 13-amyloid slow cognitive decline in
Alzheimer’s disease. Neuron 2003.38: 547-554.
Hope AD, de Silva R, Fischer DF, Hol EM, van
Leeuwen FW, Lees AJ. 2002. Alzheimer’s
associated variant ubiquitin causes inhibition of
the 26S proteasome and chaperone expression. J
Neurochem 86: 394-404.
Hsu FC, Garside MJ, Massey AE, McAllister-
Wiliams RH. 2003. Effects of a single dose of
cortisol on the neural correlates of episodic
memory and error processing in healthy volunteers.
Psychopharmacology 167:431-442.
Hyman BT, van Hoesen GW, Damasio A. 1990.
Memory-related neural systems in Alzheimer’s
disease" an anatomic study. Neurology 40:1721-
1730..
Igaz LM, Bekinschtein P, Vianna MRM, Izquierdo I,
Medina JH. 2004. Gene expression during
memory formation. Neurotox Res 6:189-204.
Igaz LM, Vianna MR, Medina JH, Izquierdo I. 2002.
Two time periods of hippocampal RNA synthesis
are required for memory consolidation of fear-
motivated learning. J Neurosci 22: 6781-6789.
Izquierdo I. 1989. Different forms of post-training
memory processing. Behav Neural Biol 51" 171-
202.
Izquierdo I. 1984. Endogenous state dependency"
Memory depends on the relation between the
neurohumoral and hormonal states present after
training and at the time of testing. In: Lynch G,
McGaugh JL, Weinberger NM, eds, Neurobiology
of Learning and Memory, New York, NY, USA:
Guilford Press; 333-350.
Izquierdo I. 1979. Effect of naloxone and morphine
on various forms of memory in the rat: Possible
role of endogenous opiate mechanisms in memory
consolidation. Psychopharmacology 1979: 66,
199-203.
Izquierdo I. 1991. Opioids and memory. In: Stone
TW, ed, Aspects of Synaptic Transmission,
London, UK: Taylor & Francis; 162-178.
Izquierdo I, Da Cunha C, Rosat R, Jerusalinsky D,
Ferreira MBC, Medina JH. 1992. Neurotransmitter
receptors involved in post-training memory
processing by the amygdala, medial septum and
hippocampus of the rat. Behav Neural Biol 58:
16-26.
Izquierdo I, Fin C, Schmitz PK, Da Silva RC, Jerusa-
linsky D, Quillfeldt JA, et al. 1995. Memory
enhancement by intrahippocampal, intra-amygdala,
or intra-entorhinal infusion of platelet-activating
factor. Proc Natl Acad Sci USA 92: 5047-5051.
Izquierdo I, McGaugh JL. 2000. Behavior pharma-
cology and its contribution to the molecular basis
of memory consolidation. Behav Pharmacol 11:
517-534.
Izquierdo I, Medina JH. 1991. GABAA receptor
modulation of memory: the role of endogenous
benzodiazepines. Trends Pharrnacol Sci 1991.12:
260-265.
Izquierdo I, Medina JH. 1997. Memory formation:
the sequence of biochemical events in thePHARMACOLOGY OF MEMORY 183
hippocampus and its connection to activity in
other brain structures. Neurobiol Learn Mem 68"
285-316.
Izquierdo I, Medina JH, Vianna MR, Izquierdo LA,
DM Barros. 1999. Separate mechanisms for short-
and long-term memory. Behav Brain Res 103" 1-11.
Izquierdo, JA, Insta JA, Biscardi AM, Izquierdo I.
1959. Some observations on the responses to
stimulation of the afferent vagus nerve. Med Exp
1: 325-332.
Izquierdo LA, Barros DM, Medina JH, Izquierdo I.
2002. Stress hormones enhance retrieval of fear
conditioning acquired one day or many months
before. Behav Pharmacol 13:203-214.
Izquierdo LA, Barros DM, Vianna MR, Coitinho A,
De David e Silva T, Choi T, et al. 2002.
Molecular pharmacological dissection of short-
and long-term memory. Cell Mol Neurobiol 22:
269-287.
Izquierdo LA, Barros DM, Medina Jl-I, Izquierdo I.
2003. Exposure to novelty enhances retrieval of
very remote memory in rats. Neurobiol Learn Mem
79:51-58.
Izquierdo LA, Barros DM, Medina JH, Izquierdo I.
2000. Novelty enhances retrieval of one-trial
avoidance learning in rats or 31 days after
training unless the hippocampus is inactivated by
different receptor antagonists and enzyme
inhibitors. Behav Brain Res 117:215-220.
Janus C. 2003. Vaccines for Alzheimer’s disease: how
close are we? CNS Drugs 17: 457-474.
Jezek K, Wesierska M, Fenton AA. 2002. Hippo-
campus-dependent retrieval and hippocampus-
independent extinction of place avoidance
navigation, and stress-induced out-of-context
activation of a memory revealed by reversible
lesion experiments in rats. Physiol Res 51 Suppl
1: $35-$47.
Jerusalinsky D, Ferreira MBC, Walz R, Da Silva RC,
Bianchin M, Ruschel AC, et al. 1992. Amnesia by
post-training infusion of glutamate receptor
antagonists into the amygdala, hippocampus and
entorhinal cortex. Behav Neural Biol 58" 76-80.
Johnston AN, Migues PV. 2001. Task- and time-
dependent memory enhancement by dehydroepi-
androsterone in day-old chicks. Neural Plast 8:
255-270.
Karas GB, Buron EJ, Rombouts SA, van Shijndel
RA, O’Brien JT, Scheltens P, et al. 2003. A
comprehensive study of gray matter loss in
patients with Alzheimer’s disease using optimized
voxel-based morphometry. Neuroimage 18: 895-
907.
Katona I, Rancz EA, Acsady L, Ledent C, Mackie,K,
Hajos N, et al. 2001. Distribution of CB1 canna-
binoid receptors in the amygdala and their role in
the control ofGABAergic transmission. J Neurosci
21: 9506-9518.
Kelly A, Laroche S, Davis S. 2003. Activation of
mitogen-activated protein kinase/extracellular
signal-regulated kinase in hippocampal circuitry
is required for consolidation and reconsolidation
ofrecognition memory. J Neurosci 23" 5354-5360.
Kemppainen N, Laine M, Laakso MP, Kaasinen V,
Nagren K, Vahlberg T, et al. 2003. Hippocampal
dopamine D2 receptors correlate with memory
functions in Alzheimer’s disease. Eur J Neurosci
18: 149-154.
Khavandgar S, Homayoun H, Zarrindast MR. 2003.
The effect of L-NAME and L-arginine on
impairment of memory formation and state-
dependent learning induced by morphine in mice.
Psychopharmacology 167: 291-296.
Kilgard M. 2003. Cholinergic modulation of skill
learning and plasticity. Neuron 38: 678-60.
Koh MT, Bernstein IL. 2003. Inhibition of protein
kinase A activity during conditioned taste aversion
retrieval" interference with extinction or recon-
solidation of a memory? Neuroreport 14" 405-
407.
Koh MT, Thiele TE, Bernstein IL. 2002. Inhibition
of protein kinase A activity interferes with long-
term, but not short-term, memory of conditioned
taste aversion. Behav Neurosci 116:1070-1074.
Konishi Y, Beach T, Sue LI, Hampel H, Lindholm K,
Shen Y. 2003. The temporal localization of frame-
shift ubiquitin-B and amyloid precursor protein,
and complement proteins in the brain of non-
demented control patients with increasing
Alzheimer’s disease pathology. Neurosci Lett
348: 46-50.
Kraus M, Schicknick H, Wetzel W, Ohl F, Staak S,
Tischmeyer W. 2002. Memory consolidation for
the discrimination of frequency-modulated tones
in mongolian gerbils is sensitive to protein
synthesis inhibitors applied to the auditory cortex.
Learn Mem 9: 293-303.
LaLumiere RT, Buen TV, McGaugh JL. 2003. Post-
training intra-basolateral amygdala infusions of
norepinephrine enhance consolidation of memory184 IVAN IZQUIERDO ET AL.
for contextual fear conditioning. J Neurosci 23:
6754-6758.
Lamirault L, Guillou C, Thai C, Simon H. 2003.
Combined treatment with galanthaminium
bromide, a new cholinesterase inhibitor, and
RS67333, a partial agonist of 5-HT4 receptors,
enhances place and objet recognition in young
adult and old rats. Prog Neuropharmacol Biol
Psychiatry 27:185-195.
Lattal KM, Abel T. 2004. Behavioral impairments
caused by injection of the protein synthesis
inhibitor anisomyxin after contextual fear retrieval
reverses with time. Proc Natl Acad Sci USA 101"
2667-2672.
Lattal KM, Abel T. 2001. Different requirements for
protein syntheis in acquisition and extinction of
spatial preferences and context-evoked fear. J
Neurosci 21" 5773-5780.
Lee AL, Ogle WO, Sapolsky RM. 2002. Stress and
depression: possible links to neuron death in the
hippocampus. Bipolar Disord 4:117-128.
Lin CH, Yeh SH, Leu TH, Chang WC, Gean PW.
2003. Identification of calcineurin as a key signal
in the extinction of fear memory. J Neurosci 23"
1574-1579.
Lin CH, Yeh SH, Lin C-H, Lu KT, Leu TH, Chang
WC, et al. 2001. A role for the PI-3 kinase
signaling pathway in fear conditioning and
synaptic plasticity in the amygdala. Neuron 31"
841-851.
Locatelli F, Maldonado H, Romano A. 2002. Two
critical periods for cAMP-dependent protein
kinase activity during long-term memory consoli-
dation in the crab Chasmagnathus. Neurobiol
Learn Mem 77: 234--249.
L6pez-Sal6n M, Alonso M, Vianna MR, Viola H,
Mello e Souza T, Izquierdo I, et al. 2001. The
ubiquitin-proteasome cascade is required for
mammalian long-term memory formation. Eur J
Neurosci 14:1820-1826.
L6pez-Sal6n M, Morelli L, Castano EM, Soto EF,
Pasquini JM. 2000. Defective ubiquitination of
cerebral proteins in Alzheimer’s disease. J Neurosci
Res 62:302-310.
L6pez-Sal6n M, Pasquini L, Besio Moreno M,
Pasquini JM, Soto E. 2003. Relationship between
beta-amyloid degradation and the 26S proteasome
in neural cells. Exp Neurol 180: 131-143.
Lu KT, Walker DL, Davis M. 2001. Mitogen-
activated protein kinase cascade in the basolateral
nucleus of amygdala is involved in extinction of
fear-potentiated startle. J Neurosci 21: RC162.
Luine VN, Jacome JF, Maclusky NJ. 2003. Rapid
enhancement of visual and place memory by
estrogens in rats. Endocrinology 144: 2836-2844.
McAll]ster-Williams RH, Rugg MD. 2002. Effects of
repeated cortisol administration on brain potential
correlates of episodic memory retrieval. Psycho-
pharmacology 160: 74-83.
McAllister-Williams RH, Massey AE, Rugg MD.
2002. Effects of tryptophan depletion on brain
potential correlates of episodic memory retrieval.
Psychopharmacology 160: 434-442.
McGaugh JL, Castellano C, Brioni J. 1990. Picro-
toxin enhances latent extinction of conditioned
fear. Behav Neurosci 104: 264-267.
McGaugh JL, Izquierdo I. 2000. The contribution of
pharmacology to research on the mechanism of
memory formation, Trends Pharmacol Sci 21:
208-210.
Mclntyre CK, Marriott LK, Gold PE. 2003. Co-
operation between memory systems: acetylcholine
release in the amygdala correlates positively with
performance on a hippocampus-dependent task.
Behav Neurosci 117: 320-326.
Mclntyre CK, Pal SN, Marriott LK, Gold PE. 2002.
Competition between memory systems: acetyl-
choline release in the hippocampus correlates
negatively with good performance on an amygdala-
dependent task. J Neurosci 22:1171-1176.
Mclntyre CK, Power AE, Roozendaal B, McGaugh
JL. 2003. Role of the basolateral amygdala in
memory consolidation. Ann NY Acad Sci 985:
273-293.
McLin DE 3rd, Miasnikov AA, Weinberger NM. 2003.
CS-specific gamma, theta, and alpha EEG activity
detected in stimulus generalization following
induction of behavioral memory by stimulation of
the nucleus basalis. Neurobiol Learn Mere 79:
152-176.
McNay EC, Gold PE. 2001. Age-related differences
in hippocampal extracellular fluid glucose
concentration during behavioral testing and
following systemic glucose administration. J
Gerontol A: Biol Sci Med Sci 56: B66-B71.
McNay EC, McCarty RC, Gold PE. 2001. Fluctua-
tions in brain glucose concentration during
behavioral testing: dissociations between brain
areas and between brain and blood. Neurobiol
Learn Mem 75: 325-327.PHARMACOLOGY OF MEMORY 185
Marsicano G, Goodenough S, Monory K, Hermann
H, Eder M, Cannich A, et al. 2003. CBI
cannabinoid receptors and on-demand defense
against excitotoxicity. Science 302: 84-88.
Marsicano G, Wojtak CT, Azad SC, Bisogno T,
Rammes G, Cascio MG, et al. 2002. The
endogenous cannabinoid system controls extinction
ofaversive memories. Nature 418: 530-534.
Martin JH. 1991. Autoradiographic matching of the
extent of reversible inactivation produced by
microinjection of lidocaine and muscimol in the
rat. Neurosci Lett 127:160-164.
Martins VR, Linden R, Prado MAM, Walz R,
Sakamoto AC, Izquierdo I, et al. 2002. Cellular
prion protein: on the road for functions. FEBS
Lett 512: 25-28.
Matthies H. 1989. In search ofthe cellular mechanisms
ofmemory. Prog Neurobio132: 277-349.
Medina JH, Izquierdo I. 1995. Retrograde
messengers, long-term potentiation and memory
processes. Brain Res Rev 21" 185-194.
Meneses A. 2001. Could the 5HT1B receptor inverse
agonism affect learning consolidation? Neurosci
Biobehav Rev 25: 193-201.
Meneses A. 2002. Involvement of 5HT(2A/2B/2C)
receptors on memory formation: simple agonism,
antagonism or inverse agonism? Cell Mol
Neurobio122: 675-688.
Metzger MM, Flint RW Jr. 2003. Glucose enhance-
ment of face recognition is unaffected by
alterations of face features. Neurobiol Learn Mere
80:172-175.
Milekic M, Alberini CM. 2002. Temporally graded
requirement for protein synthesis following
memory reactivation. Neuron 38: 521-525.
Miranda ML, Ferreira G, Ramfrez-Lugo L, Bermtdez-
Rattoni F. 2002. Glutamatergic activity in the
amygdala signals visceral input during taste
memory formation. Proc Natl Acad Sci USA 99:
11417-11422.
Miserendino MJ, Sananes CB, Melia KR, Davis, M.
1990. Blocking of acquisition but not expression
of conditioned fear-potentiated startle by NMDA
antagonists in the amygdala. Nature 345:716-718.
Mishima K, Egashira N, Hirosawa N, Fujii M,
Matsumoto Y, Iwasaki K, et al. 2001. Charac-
teristics of learning and memory impairment
induced by delta9-tetrahydrocannabinol in rats.
Jpn J Pharmacol 87: 297-308.
Morris RGM, Anderson E, Lynch GS, Baudry M.
1986. Selective impairment of learning and
blockade of long-term potentiation by an N-
methyl-D-aspartate receptor antagonist, AP5.
Nature 297: 681-683.
Myers KM, Davis M. 2002. Behavioral and neural
analysis of extinction. Neuron 567-584.
Nader K. Memory traces unbound. 2002. Trends
Neurosci 26: 65-72.
Nader K, Schafe GE, Le Doux JE. 2000. Fear
memories require protein synthesis in the amygdala
for reconsolidation. Nature 406: 722-726.
Nakazawa K, Sun LD, Quirk MC, Rondi-Reig L,
Wilson MA, Tonegawa S. 2003. Hippocampal
CA3 NMDA receptors are crucial for memory
acquisition on one-time experience. Neuron 147-
148.
Orsetti M, Ferretii C, Gamalero R, Ghi P. 2002.
Histamine H3-receptor blockade in the rat nucleus
basalis magnocellularis improves place recognition
memory. Psychopharmacology 159:133-137.
Orsetti M, Ghi P, Di Caro G. 2001. Histamine H(3)-
receptor antagonism improves memory retention
and reverses the cognitive deficit induced by
scopolamine in a two-place recognition task.
Behav Brain Res 124: 235-242.
Paban V, Soumireu-Mourat B, Alescio-Lautier B.
2003. Behavioral effects of arginine-8-vaso-
pressoin in the Hebb-Williams maze. Behav Brain
Res 141: 1-9.
Packard MG, Vecchioli SF, Schroeder JP, Gasbarri
A. 2001. Task-dependent role for dorsal striatum
metabotropic glutamate receptors in memory.
Learn Mem 8: 96-103.
Paquette V, Levesque J, Mansour B, Leroux JM,
Beaudoin G, Borgouin P, et al. 2003. Change the
mind and you change the brain: effects of
cognitive-behavioral therapy on the neural
correlates of spider phobia. Neuroimage 18: 401-
409.
Pakaski M, Kasa P. 2003. Role of acetylcholin-
esterase inhibitora in the metabolism of amyloid
precursr protein. Curr Drug Targets CNS Neurol
Disord 2:163-171.
Paratcha G, Furman M, Bevilaqua L, Cammarota M,
Vianna M, de Stein ML, et al. 2000. Involvement
of hippocampal PKCI3 isoform in the early
phase of memory formation of an inhibitory
avoidance learning. Brain Res 855" 199-205.
Paratcha G, Ledda F, Ibanez CF. 2003. The neural
cell adhesion molecule NCAM is an alternative186 IVAN IZQUIERDO ET AL.
signaling receptor for GDNF family ligands. Cell
113: 867-879.
Passani MB, Cangioli I, Baldi E, Bucherelli C,
Mannaioni PF, Blandina P. 2001. Histamine H3
receptor-mediated impairment of contextual fear
conditioning and in vivo inhibition of cholinergic
transmission in the rat basolateral amygdala. Eur J
Neurosci 14: 1522-1532.
Pereira GS, Mello e Souza T, Battastini AMO,
Izquierdo I, Sarkis JJF, Bonan CD. 2002. Effects
of inhibitory avoidance training and/or isolated
foot-shock on ectonucleotidase activities in
synaptosomes from the anterior and posterior
cingulate cortex and the medial precentral area of
adult rats. Behav Brain Res 128:121-127
Pereira GS, Walz R, Bonan CD, Battastini AMO,
Izquierdo I, Martins VR, et al. 2001. Changes in
cortical and hippocampal ectonucleotidase
activities in mice lacking cellular prion protein.
Neurosci Lett 301" 72-74.
Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH.
Increased Alzheimer pathology in Parkinson’s
disease related to antimuscarinic drugs. Ann
Neurol 2003.54: 235-238.
Picada JN, Schr6der N, Izquierdo I, Henriques JAP,
Roesler R. 2002. Differential neurobehavioral
deficits induced by apomorphine and its oxidation
product, 8-oxo-apomorphine-semiquinone, in rats.
Eur J Pharmacol 443:105-111.
Pitsikas N, Rigamonti AE, Celia SG, Muller EE.
2002. Effect of the nitric oxide donor molsido-
mine on different memory components as
assessed in the object-recognition task in rats.
Psychopharmacology 162: 239-245.
Porciuncula L, Schmidt A, Coitinho AS, Vinad6 E,
Izquierdo I, Rocha J, et al. 2002. Intrahippo-
campal infusion of ebselen impairs retention of an
inhibitory avoidance task in rats. Eur J
Pharmacology 451: 165-168.
Porter AC, Sauer JM, Knierman MD, Becker GW,
Berna MJ, Bao J, et al. 2002. Characterization of
a novel endocannabinoid, virodhamine, with
antagonistic activity at the CB1 receptor. J
Pharmacol Exp Ther 301:1020-1024.
Power AE, Vazdarjanova A, McGaugh JL. 2003.
Muscarinic cholinergic influences in memory con-
solidation. Neurobiol Learn Mem 80" 178-193.
Prado-Alcal. 1995. Serial and parallel processing
during memory consolidation. In: McGaugh JL,
Bermudez-Rattoni FE, Prado-AlcalCt RA, eds,
Plasticity in the Central Nervous System. Mahwah,
New Jersey, USA: Lawrence Erlbaum; 171-184.
Prado-Alcal RA, Ruiloba MI, Rubio L, Solana-
Figueroa R, Medina C, Salado-Castillo R, et al.
2003. Regional infusions of serotonin into the
striatum and memory consolidation. Synapse 47"
169-175.
Quevedo J, De-Paris F, Vianna MR, Barichello T,
Roesler R, Kapczinski F. 2002. Interaction between
midazolam-induced anterograde amnesia and
memory enhancement by treatments given
immediately after training on an inhibitory
avoidance task in rats. Behav Pharmacol 13" 319-
322.
Qiu J, Bosch MA, Tobias SC. Grandy DK, Scanlan
TS, Ronnekiev OK, et al. 2003. Rapid signaling
of estrogen in hippocamthalamus neurons involves
a novel G-protein-coupled estrogen receptor that
activates protein kinase C. J Neurosci 2003.9529-
9540.
Ressler KJ, Paschall G, Zhou XL, Davis M. 2002.
Regulation of synaptic plasticity genes during
consolidation of fear conditioning. J Neurosci 22:
7892-7902.
Riedel G. 1996. Function of metabotropic glutamate
receptors in learning and memory. Trends
Neurosci 19:219-224.
Riedel G, Platt B, eds. 2004 (in press). Memories are
Made of These: From Messengers to Molecules.,
London, UK: Landes Bioscience/Eureka Pubmed.
http://www.eurekah.com/isbn,php?isbn=0-306-
47862-5&bookid=97&catid=48
Riedel G, Platt B, Micheau J. 2003. Glutamate
receptor function in learning and memory. Behav
Brain Res 140" 1-47.
Rodrigues SM, Bauer EP, Farb CR, Schaf6 GE,
LeDoux JE. 2002. The group metabotropic
glutamate receptor mGluR5 is required for fear
memory formation and long-term potentiation in
the lateral amygdala. J Neurosci 22: 5219-5229.
Rodrigues SM, Schaf6 GE, LeDoux JE. 2001. Intra-
amygdala blockade of the NR2B subunit of the
NMDA receptor disrupts the acquisition but not
the expression of fear conditioning. J Neurosci
21: 6889-6896.
Roesler R, Meller A, Kopshina MI, Souiza DO,
Henriques JA, Schwartsmann. 2003. Intrahippo-
campal infusion ofthe bombesin/gastrin-releasing
peptide antagonist RC3095 impairs inhibitory
avoidance retention. Peptides 24: 1069-1074.PHARMACOLOGY OF MEMORY 187
Roesler R, Schr6der N, Vianna MR, Quevedo J,
Bromberg E, Kapczinski F, et al. 2003. Differential
involvement of hippocampal and NMDA receptors
in contextual and aversive aspects of inhibitory
avoidance memory in rats. Brain Res 975: 207-213.
Rogers JL, Kesner RP. 2003. Cholinergic modulation
of the hippocampus during encoding and retrieval.
Neurobiol Learn Mem 80: 332-342.
Roldfin G, Cobos-Zapiain G, Quirarte GL, Prado-
Alcalf RS. 2001. Dose- and time-dependent scop-
olamine-induced recovery of an inhibitory
avoidance response after its extinction in rats.
Behav Brain Res 121" 173-179.
Roozendaal B. 2002. Stress and memory: opposing
effects of glucocorticoids on memory consoli-
dation and memory retrieval. Neurobiol Learn
Mem 78: 578-595.
Roozendaal B, Griffith QK, Buranday J, de Quervain
DJ, McGaugh JL. 2003. The hippocampus
mediates glucocorticoid-induced impairment of
spatial memory retrieval: dependence on the
basolateral amygdala. Proc Natl Acad Sci USA
100: 1328-1333.
Roozendaal B, Phillips RG, Power AE, Brooke SM,
Sapolsky RM, McGaugh JL. 2001. Memory
retrieval impairment induced by hippocampal
CA3 lesions is blocked by adrenocortical
suppression. Nat Neurosci 4:1169-1171.
Roozendaal B, Quirarte GL, McGaugh JL. 2002.
Glucocorticoids interact with the basolateral
amygdala beta-adrenoceptor-cAMP/cAMP/PKA
system in influencing memory consolidation. Eur
J Neurosci 15:553-560.
Rosatto J, Bonini JS, Coitinho AS, Vianna MR,
Medina JH, Cammarota M, et al. 2004. Retro-
grade amnesia induced by drugs acting on
different molecular systems depends on how long
after training these drugs are infused in selected
brain areas. Behav Neurosci 118: 563-568.
Rose JK, Kaun KR, Chen SH, Rankin CH. 2003.
GLR-1, a non-NMDA glutamate receptor homolog,
is critical for long-term memory in Caeno-
rhabditis elegans. J Neurosci 23: 9595-9599.
Rose SPR. 1995. Time-dependent biochemical and
cellular processes in memory formation. In:
McGaugh JL, Bermudez-Rattoni FE, Prado-Alcal
RA. Plasticity in the Central Nervous System.
Mahwah, New Jersey, USA’. Lawrence Erlbaum;
171-184.
Rothbaum BO, Schwartz AC. 2002. Exposure therapy
for posttraumatic stress disorder. Am J Psychother
56: 59-75.
Routtenberg A. 2000. It’s about time. In: Gold PE,
Greenough WT, eds, Memory Consolidation.
Waslington, DC, USA: American Psychological
Association; 17-34.
Routtenberg A. 1995. Knockout mouse fault lines.
Nature 374: 314-315.
Roy M, Sapolsky RM. 2003. The exacerbation of
hippocampal excitotoxicity by glucocorticoids is
not mediated by apoptosis. Neuroendocrinology
77:24-31.
Sachetti B, Lorenzini CA, Baldi E, Tassoni G,
Bucherelli C. 1999. Auditory thalamus, dorsal
hippocampus, basolateral amygdala, and perirhinal
cortex role in the consolidation of conditioned
freezing to context and to acoustic conditioned
stimulus in the rat. J Neurosci 19" 9570-9578.
Sanders MJ, Fanselow MS. 2003. Pre-training prevents
context fear conditioning deficits produced by
hippocarripal NMDA receptor blockade. Neurobiol
Learn Mem 80: 123-129.
Sapolsky RM. 2001. Atrophy of the hippocampus in
posttraumatic stress disorder: how and when?
Hippocampus 11" 90-91.
Sandi C, Merino JJ, Cordero MI, Kruyt ND, Murphy
KJ, Regan CM. 2003. Modulation ofhippocampal
NCAM polysialylation and spatial memory con-
solidation by fear conditioning. Biol Psychiatry
54: 599-607.
Savage LM, Chang Q, Gold PE. 2003. Diencephalic
damage decreases hippocampal acetylcholine
release during spontaneous alternation testing.
Learn Mem 10: 242-246.
Schelling G. 2002. Effects of stress hormones on
traumatic memory formation and the development
of posttraumatic stress disorder in critically ill
patients. Neurobiol Learn Mem 78: 596-609.
Schroeder JP, Packard MG. 2002. Post-training intra-
basolateral amygdala scopolamine impairs food-
and amphetamine-induced conditioned place
preferences. Behav Neurosci 116" 922-927.
Schroeder JP, Packard MG. 2003. Systemic or intra-
amygdala injections of glucose facilitate memory
consolidation for extinction of drug-induced
conditioned reward. Eur J Neurosci 17:1482-1488.
Shansis FM, Busnello JV, Quevedo J, Forster L,
Young S, Izquierdo I, et al. 2000. Behavioural
effects of acute tryptophan depletion in healthy
male volunteers. J Psychopharmacol 14: 157-163.188 IV/kN IZQUIERDO ET AL.
Schmitt U, Hiemke C. 2002. Tiagabine, a gamma-
amino-butyric transporter inhibitor impairs spatial
learning of rats in the Morris water maze. Behav
Brain Res 133" 391-394.
Selcher JC, Weeber EJ, Christian J, Nekrasova T,
Landreth GE, Sweatt JD. 2003. A role for ERK
MAP kinase in physiologic temporal integration
in hippocampal area CA1. Learn Mem 10: 26-39.
Shinotoh H, Fukushi K, Nagtsuka S, Tanaka N,
Aotsuka A, Ota T, et al. 2003. The amygdala and
Alzheimer’s disease: positron emission tomo-
graphic study of the cholinergic system. Ann NY
Acad Sci 985: 411-419.
Sergeant N, Bombois S, Ghestem A, Drobecq H,
Kostanjevecki V, Missiaen C, et al. 2003.
Truncated beta-amyloid peptide species in pre-
clinical Alzheimer’s disease as new targets for the
vaccination approach. J Neurochem 85: 1581-
1591.
Southwick SM, Davis M, Horner B, Cahill L,
Morgan CA 3 rd, Gold PE, et al. 2002. Relation-
ship of enhanced norepinephrine activity during
memory consolidation to enhanced long-term
memory in humans. Am J Psychiatry 159: 1420-
1422.
Stephenson CM, Suckling J, Dirckx SG, Ooi C,
McKenna PJ, Bisbrown-Chippendale R, et al.
2003. GABAergic inhibitory mechanisms for
repetition-adaptivity in large-scale brain systems.
Neuroimage 19:1578-1588.
Straube T, Frey JU. 2003. Involvement of beta-
adrenergic receptors in protein synthesis-
dependent long-term potentiation (LTP) in the
dentate gyrus of freely moving rats: the critical
role ofLTP induction strength. Neuroscience 119:
473-479.
Summers MJ, Crowe SF, Ng KT. 2003. Memory
retrieval in the day-old chick: a psychobiological
approach. Neurosci Biobehav Rev 27:219-231.
Sunram-Lea SI, Foster JK, Durlach P, Perez C. 2002.
The effect of retrograde and anterograde glucose
on memory performance in healthy young adults.
Behav Brain Res 134: 505-516.
Szapiro G., Barros DM, Ardenghi P, Vianna MR,
Choi H, Silva T, et al. 2001. Facilitation and
inhibition of retrieval in two aversive tasks in rats
by intrahippocampal infusion of agonists of
specific glutamate metabotropic receptor subtypes.
Psychopharmacology 156:397-401.
Szapiro G, Izquierdo LA, Alonso M, Barros DM,
Paratcha G, Ardenghi P, et al. 2000. Participation
ofhippocampal metabotropic glutamate receptors,
protein kinase A and mitogen-activated protein
kinases in memory retrieval. Neuroscience 99: 1-5.
Szapiro G, Vianna MR, McGaugh JL, Medina JI-I,
Izquierdo I. 2003. The role ofNMDA glutamate
receptors, PKA, MAPK, and CAMKII in the
hippocampus in extinction of conditioned fear.
Hippocampus 13" 53-58.
Talley CP, Clayborn H, Jewel E, McCart R, Gold PE.
2002. Vagotomy attenuates effects of L-glucose
but not D-glucose on spontaneous alternation
performance. Physiol Behav 77: 243-249.
Taubenfeld SM, Milekic MH, Monti B, Alberini CM.
2001. The consolidation of new but not
reactivated memory requires hippocampal C/EBP
beta. Nat Neurosci 4:813-818.
Taubenfeld SM, Wiig KA, Bear MF, Alberini CM.
1999. A molecular correlate of memory and
amnesia in the hippocampus. Nat Neurosci 2:
309-310.
Taubenfeld SM, Wiig KA, Monti B, Dolan B,
Pollonini G, Alberini CM. 2001. Fornix-depen-
dent induction of hippocampal CCAAT enhancer-
binding brotein [beta] and [delta] co-localizes
with phosphoryqated cAMP response element-
binding protein and accompanies long-term
memory consolidation. J Neurosci 21" 84-91.
Tronel S, Sara SJ. 2003. Blockade ofNMDA receptors
in prelimbic cortex induces an enduring amnesia
for odor-reward associative learning. J Neurosci
2003.23: 5472-5476.
Vallee M, Purdyu RH, Mayo W, Koob GF, LeMoal
M. 2003. Neuroactive steroids: new biomarkers of
cognitive aging. J Steroid Biochem Mol Biol 85:
329-335.
Vianna M.R., Alonso M., Viola H., Quevedo J., de-
Paris F, Furman, M, ET AL. 2000. Role of
hippocampal signaling pathways in long-term
memory formation of a nonassociative learning
task in the rat. Learn Mem 7: 333-340.
Vianna, MR, Cammarota M, Coitinho AS, Medina
JH, Izquierdo I. 2003. Pharmacological findings
on the molecular basis ofmemory extinction. Curr
Neuropharmacol 1: 109-121.
Vianna MR, Coitinho A, Izquierdo I. 2004. Role of
the hippocampus and amygdala in the extinction
of fear-motivated learning. Curr Neurovasc Res 1:
55--60.
Vianna MR, Igaz LM, Coitinho AS, Medina JH,PHARMACOLOGY OF MEMORY 189
Izquierdo I. 2003. Memory extinction requires
gene expression in rat hippocampus. Neurobiol
Learn Mem 79: 199-203.
Vianna MR, Izquierdo LA, Barros DM, Ardenghi
PG, Pereira P, Rodrigues C, et al. 2000.
Differential role of cAMP-dependent protein
kinase in short-and long-term memory. Neurochem
Res 25: 621-626.
Vianna MR, Szapiro G, McGaugh JL, Medina JH,
Izquierdo, I. 2001. Retrieval of memory for fear-
motivated training initiates extinction requiring
protein synthesis in the rat hippocampus. Proc
Natl Acad Sci USA 98:12251-12254.
Viola H, Furman M, Izquierdo LA, Alonso M, Barros
DM, De Souza MM, et al. 2000. Phosphorylated
cAMP response element-binding protein as a
molecular marker of memory: Effect of novelty. J
Neurosci 20" RC 112, 1-5.
Walker DL, Ressler KT, Lu KT, Davis M. 2002.
Facilitation of conditioned fear extinction by
systemic administration or intra-amygdala infusions
of D-cycloserine as assessed with fear-potentiated
startle in rats. J Neurosci 22: 2343-2351.
Walz R, Lenz G, Roesler R, Vianna MR, Martins V,
Brentani RR, et al. 2000. Time-dependent
enhancement of inhibitory avoidance retention
and MAPK activation by post-training infusion of
nerve growth factor into CA1 region of
hippocampus of adult rats. Eur J Neurosci 12,
2185-2189.
Walz R, Roesler R, Quevedo J, Rockenbach IC,
Amaral OB, Vianna MR, et al. 1999a. Dose-
dependent impairment of inhibitory avoidance
retention in rats by imediate post-training infusion
of a mitogen-activated protein kinase kinase
inhibitor into cortical structures Behav Brain Res
105:219-223.
Walz R, Roesler R, Barros DM, de Souza MM,
Rodrigues C, Sant’Anna MK, et al. 1999b.
Izquierdo I. Effects of post-training infusions of a
mitogen-activated protein kinase kinase inhibitor
into the hippocampus or entorhinal cortex on
short- and long-term retention of inhibitory
avoidance. Behav Pharmacol 10: 723-730.
Weeber EJ, Sweatt JD. 2002. Molecular neuro-
biology ofhuman cognition. Neuron 33: 845-848.
Weeber EJ, Yiang YH, Elgersma Y, Varga AW,
Carrasquillo Y, Brown SE, et al. 2003. Derange-
ments of hippocampal calcium/calmodulin-
dependent protein kinase II in a mouse model for
Angelman mental retardation syndrome. J Neurosci
23: 2634-2644.
Weinberger NW. 2003. The nucleus basalis and
memory codes: Auditory cortical plasticity and
the induction of specific, associative behavioral
memory. Neurobiol Learn Mem 80: 268-284.
Wetzel W, Ott T, Matthies H. 1976. Is actinomycin D
suitable for the investigation ofmemory processes?
Pharmacol Biochem Behav 1976.4:515-519.
Wilson RI, Nicoll RA. 2001. Endogenous canna-
binoids mediate retrograde signaling at hippo-
campal synapses. Nature 41 566-592.
Wilson RI, Nicoll RA. 2002. Endocannabinoid
signaling in the brain. Science 296" 678-682.
Wilson MA, Tonegawa S. 1997. Synaptic plasticity,
place cells and spatial memory: study with second
generation knockouts. Trends Neurosci 20: 102-
106.
Xu AJ, Chen Z, Wanai K, Huang YW, Wei EQ. 2002.
Effect of 3-1-(phenylmethyl)-4-piperidinyl]- 1- (2,3,
4,5-tetrahydro- H- 1-benzazepin-8-yl)-l-propanone
fumarate, a novel acethylcholinesterase inhibitor,
on spatial cognitive impairment induced by
chronic cerebral hypoperfusion in rats. Neurosci
Lett 331: 33-36.
Xu X, Bazner J, Qi M, Johnson E, FreidhoffR. 2003.
The role of telencephalic NMDA receptors in
avoidance learning in goldfish (Carassius
auratus). Behav Neurosci 117: 548-554.
Yang Y, Cao J, Xiong W, Zhang J, Zhou Q, Wei H,
et al. 2003. Both stress experience and age
determine the impairment or enhancement of
stress on spatial memory retrieval. J Endocrinol
178: 45-54.
Zhen X, Du W, Romano AG, Friedman E, Harvey
JA. 2001. The p38 mitogen-activated protein
kinase is involved in associative learning in
rabbits. J Neurosci 21" 5513-5519.
Zhu X, Sun Z, Lee HG, Siedlak SL, Perry G, Smith
MA. 2003. Distribution, levels, and activation of
MEK1 in Alzheimer’s disease. J Neurochem 86:
136-142.